

## Index

- Abbott Laboratories case, drug patent settlement in, 320–1
- Abbreviated New Drug Application (ANDA), 22–3, 25–6  
 product hopping cases and, 27, 38–9  
 reverse payment cases and, 26–7, 32–8
- AB rating  
 brand/generic drug regulations and, 25–6  
 monopoly power screen and, 28–32  
 product hopping cases and, 38–9
- AB Volvo and Erik Veng*, 97–100, 108–11
- Acacia Technologies, 257–8
- acceleration clauses, in patent drug settlements, 322–4
- Acme Precision Products, Inc. v. Am. Alloys Corp.*, 275–7
- adaptation, copyright protection and, 210
- Addanki, Sumanth, 21–41
- additional abusive conduct principle, intellectual property and, 108–9
- AdMob, Google acquisition of, 461
- advertising  
 Big Data consumer targeting and, 296  
 of branded drugs, 29–30  
 comparative advertising defense, 199–200  
 horizontal mergers in, 461  
 impact on search results of, 301–3  
 market definition and, 189–91, 310  
 by pharmaceutical industry, 30–1  
 trademark protection and, 199–200, 210–11  
*Walker Process* standards and, 274–5
- Airtours* case, 109–10
- AKZO* case, 109–10
- Allied Orthopedic Appliances Inc. v. Tyco Health Care Group L.P.*, 87–9, 398–401
- Almunia, J., 351–2
- Alstyne, M.W., 44–5
- America Invents Act, 262–3
- American Infra-Red Radiant Co. v. Lambert Industries, Inc.*, 288–92
- American Intellectual Property Law Association (AIPLA), 326–7
- American Needle* case, 193
- Anderman, S.D., 97–106
- anticompetitive practices  
 cable and satellite copyright and, 345–6  
 complementarity in, 142–3  
 disclosure requirements and deception as, 236–8  
 in drug patent cases, 321–2  
 in Japanese antimonopoly regulations, 139–43, 152–3  
 in Korean IFP law, 158–63, 169–70, 174–5  
 Microsoft lawsuit and, 10–12  
 non-patent litigation and, 288–92  
 patent assertion entities and, 263–5  
 patent pooling and collusion as, 367–72  
 post-expiration royalties and, 238–41  
 product hopping and, 87–9  
 resale price maintenance as, 425–7, 433–4  
 reverse payment cases, 32–8  
 tied products/tying arrangements as, 404–7, 409–18  
 US government investigation of, 225–9
- Anti-Monopoly Bureau (Korea), 159–60
- Anti-Monopoly Commission (AMC) (China), 122  
 FRAND obligations and, 127–9  
 future challenges for, 135–6  
 Market Definition, 122–3
- Anti-Monopoly Law (AML) (China)  
 establishment of, 120–1, 468–70  
 holdup of patents and, 256–7  
 IP–antitrust provisions, 121–9, 229–31

- Anti-Monopoly Law (AML) (China) (cont.)  
 patent law and, 129–30
- Antimonopoly Law (AML) (Japan)  
 Article 2 provisions, 140  
 Article 3 of, 139–40  
 Article 19 provisions, 141–2, 150–2  
 Article 21 provisions, 143–4, 147–51  
 complementarity with intellectual property of, 142–3  
 expired or exhausted patent restriction, 148–9  
 FRAND licensing obligations and, 233–4  
 future challenges for, 155  
 JFTC guidelines and, 138  
 patent and trademark applications and, 145  
 patent infringement and, 145–6  
 unilateral refusal to license in, 146–7
- Antitrust Modernization Commission (AMC), 396–7
- antitrust policy  
 Anti-Monopoly Law in China and, 121–9  
 applications of, 85–91  
 Big Data regulation and, 293–313  
 in China, 120–36, 467–8  
 complementarity in EU concerning, 106–8  
 complementarity in Japanese law on, 142–3  
 cooperative commercialization and, 15–16  
 coordinated vs. single firm conduct,  
 pharmaceuticals industry, 26–39  
 data-driven mergers and defenses and, 304–5  
 drug patent settlements, 319–36  
 economics and, 82–3  
 entrant innovation and, 9–10  
 in European Union law, 92–117  
 exceptionalism and, 98–106  
 high technology and limits of, 384–7  
 holdup of patents and, 248–9  
 implied immunity in, 56  
 injunctions for patent infringement and, 72  
 innovation economics and, 3–6, 47–9  
 intellectual property intersection with, 18–19,  
 81–93  
 in Japan, 138–55  
 limits of market definition for, 194–6  
 litigation costs as antitrust injury, 272 n.4  
 market definition and prices in, 188–9  
 network effects and, 45–6  
 non-discrimination in FRAND licensing and,  
 69–70  
 patent assertion entities and, 263–5  
 in pharmaceuticals, 21–41  
 profits of innovation and, 7–9  
 rule-based approach to EU intellectual property  
 involving, 116–17  
 Schumpeterian competition and, 49–51  
 sham litigation doctrine and, 281–8  
 support for exceptionalism in EU for, 101–2  
 tied products/tying arrangements and, 11–12,  
 404–7  
 Walker Process doctrine and, 272–81  
 welfare consequences of monopolization and,  
 82–3
- Apple, Inc. v. Motorola*, 251–5  
*Apple, Inc. v. Motorola Mobility, Inc.*, 290–1  
*Apple, Inc. v. Samsung Electronics Co.*, 290–1  
 Apple Computer  
 European litigation involving, 231–3  
 patent holdup violations, 251–5  
 in *Samsung Electronics* case, 176
- Applied Materials/Tokyo Electron merger, 163
- arbitration, FRAND licensing as, 68–9
- Areeda, Phillip, 284, 417–18, 438–9
- ARM Limited–Giesecke & Devrient GmbH–  
 Gemalto N.V. merger, 474–6
- Armstrong, M., 44–5
- asset specificity, holdup of patents and, 61
- assign back. *See* grantbacks in patent law
- AstraZeneca v. Commission*, 101–2
- Atkinson, R.D., 47–9
- AT&T-DirecTV merger, 455–8, 462–4
- AT&T-T-Mobile merger, 458–62
- audiovisual works, EU copyright rules on, 348–9
- Audretsch, D.B., 47–9
- “authorized generics,” drug patent settlements  
 and, 322–4
- Babies “R” Us, coercion of suppliers by, 427–34
- “balancing” approach, complementarity and,  
 106–7
- bargaining power, of IT mergers, 462–4
- “baseball style” arbitration, FRAND licensing and,  
 68–9
- Baxter, William F., 84–5
- Bayer AG v. Söllhöfer*, 115
- below cost pricing, innovation and antitrust  
 policies and, 4
- Bement v. National Harrow*, 89, 368–9
- benchmarking framework, in FRAND licensing,  
 69–70
- Big Data  
 accessibility, collectivity and cheapness of,  
 298–9  
 antitrust regulation and, 293–313  
 applicability of antitrust law to, 308–12  
 appropriateness of antitrust remedies in, 311–12  
 case-law on, 308–10  
 consumer protection issues and, 294–6, 310–11  
 data-driven mergers and defenses, 304–5  
 economies of scale and, 305–8

- entry barriers and, 297–8, 305–8  
 harm to competition from, 294–5, 300–8  
 innovation impact of, 296–7, 301–3  
 limitations of, 299–300  
 loss of quality impact of, 301–3  
 monetization of, 296  
 network effects of, 305–8  
 non-durability of, 299  
 nonexclusive/nonrivalrous content of, 299  
 overview of research on antitrust and, 294–5  
 platform differentiation and, 300  
 privacy, harm from, 303–4  
 procompetitive benefits of, 296–300  
 product market for, 310  
 quality improvement and innovation  
   enhancement with, 296–7  
 “Big Six” Hollywood producers, EC Statement of  
   Objections to, 341, 351–2  
 bioequivalence principle  
   “AB rating” and, 25–6  
   FDA brand and generic drug approval process  
   and, 22–3  
 Blair, Roger D., 204–20  
 blanket licensing, 358–9  
 block-booking practices. *See also* geo-blocking  
   copyright protection and, 411–12  
   sufficient economic power principle and, 415–17  
 Block Exemption Regulation (EU),  
   complementarity and, 107–8  
 blocking of patents, patent pooling and, 361–2  
 Boliek, Babette E., 43–56  
 Bork, Robert, 406–7  
 “bottom-feeder” patent assertion entities, 260–1  
 boundary delineation, patent pooling and, 364–6  
 Bowman, Ward, 84–5  
 branded drug products  
   development of, 21–2  
   European patent settlements and, 332–5  
   FDA approval of, 22–3  
   litigation costs for challenges to, 326–7  
   market definition and, 189–91  
   monopoly power screen and, 28–32  
   payment for unrelated services in settlements  
   involving, 327–8  
   payment issues in drug patent settlements and,  
   322–4  
   product hopping cases and, 27, 38–9  
   regulations governing, 25–6  
   reverse payment cases and, 32–8, 319–20  
 branding  
   antitrust and IP and, 183–4  
   interbrand/intrabrand competition, 184  
   market definition and, 189–91  
 Brennan, T.J., 19  
 brick-and-mortar retailers  
   resale price maintenance in online markets and,  
   427–34  
   scanner data from, 434 n.35  
 broadband markets  
   innovation in, 51–2  
   net neutrality and, 53–4  
*Broadcom v. Qualcomm*, 225–9, 249–50  
*Bronner v. Mediaprint*, 102  
*Brulotte v. Thys Co.*, 87, 127, 238–41  
 bundled products  
   antitrust law and, 11–12, 379–401  
   discounts and rebates on, 394–8  
   essential facilities doctrine concerning, 391  
   in FRAND licensing, 255–8  
   growth in information technology and, 384–7  
   innovation and, 392–4  
   Internet economics and, 43  
   loyalty discounts for, 398–401  
   in NDRC (China) Qualcomm case, 133–5,  
   480–1  
   patent pooling and, 362–3  
   portfolio effects of mergers and, 388–90  
   pricing in patent pools vs. conventional  
   bundling, 366–7  
 burdens of proof, in resale price maintenance  
   litigation, 435  
 business practices of SEPs, FRAND licensing and,  
   73  
 Cable and Satellite Directive (EU), 344–8. *See also*  
   Green Paper of the European Commission  
   cross-border transmission and, 344–5  
   digital single market strategy and review of,  
   350–1  
   export prohibitions in, 345–6  
   *Murphy* case and interpretation of, 347–8  
   national law of Member States and, 353 n.64  
 cable modem providers, net neutrality and, 46–7  
 cable transmission copyright  
   EU Cable and Satellite Directive, 344–5  
   *Murphy* case and, 345–8  
 cable transmissions, European Cable and Satellite  
   directive and, 344–8  
 California Air Resources Board (CARB), 287–8  
*California Computer Products Inc. v. International*  
*Bus. Mach. Corp.*, 380–4  
*California Motor Transport Co. v. Trucking*  
*Unlimited*, 282  
 Canada, drug patent settlements in, 335–6  
 Cannon, Joseph P., 430–1  
 Capital One, patent challenge by, 262–5  
 Carlton, Dennis W., 69–70, 386–7  
 Carrier, Michael A., 84–5, 319–36

- cartels  
 Japanese antimonopoly restrictions on, 140  
 monopolization and, 82–3  
 patent pooling by, 367–72  
 patent pooling exclusivity and, 369–72  
*Cascade Health Solutions v. Peacehealth* case, 396–7  
 cash payments, in patent drug settlements, 322–4  
 categorization  
 applications of antitrust and, 87, 89  
 in Chinese IP–antitrust regulatory practices, 121–9  
 causal connection test, standard-setting approach  
 to patent protection and, 288–92  
 causation, in drug patent settlements, 331  
 chain of production  
 damages for SEP infringement and, 73–5  
 net neutrality and, 46–7  
 Charter of Fundamental Rights of the European Union, 107–8  
 Charter-TWC merger, 455–8, 462–4  
 Cheng, Thomas K., 120–36  
 Chicago School of Law and Economics, tied  
 products/tying arrangements and, 406–7  
 China. *See* People’s Republic of China  
 Chinese Patent Law, 129–30  
 chip technology  
*Broadcom v. Qualcomm* case and, 226  
 Korean *Qualcomm* case involving, 173–4, 234–5  
*Qualcomm* case in China and, 480–1  
 claim construction doctrine, market definition  
 and, 200–1  
 Clayton Antitrust Act (U.S.), 248–9, 389–90,  
 392–4, 407–9, 418–21, 446–53  
 “click-and-query data,” 296–7  
 impact on quality and innovation of, 301–3  
 network effects and, 305–8  
 Coase, Ronald, 364–5  
 code division multiple access standards (CDMA,  
 WCDMA)  
 Chinese IP regulations and, 131  
 European litigation concerning, 231–3  
 FRAND licensing and, 226  
 Japanese litigation concerning, 233–4  
 Korean investigation of *Qualcomm* and, 234–5  
*Samsung Electric* case (Korea), 176  
*Coditel I and II* cases, 97–8, 341–6, 354  
 coercive business tactics  
 disclosure and deception violations and, 236–8  
 resale price maintenance in online markets and,  
 428–9  
 tying arrangements and, 413–15  
 collusion. *See also* coordinated conduct; joint  
 conduct  
 applications of antitrust and, 85–91  
 express collusion, 368–9  
 Japanese antimonopoly restrictions on, 140  
 patent pooling and threat of, 367–72  
 resale price maintenance facilitation of, 433–4  
 Colomo, Pablo Ibáñez, 339–55  
 Comanor, William, 428–9  
 Comcast/NBU merger, 455–8, 462–4  
 Comcast–TWC–Charter merger, 455–8, 462–4  
 Comerford, Roisin, 293–313  
 commerce, tied products/tying arrangements effect  
 on, 417  
 Communications Act (U.S.), 53  
 merger review process and, 452–3  
 comparative advertising defense, trademark  
 protection and, 199–200  
 competition  
 Big Data impact on, 293–4, 300–8  
 Chinese IP–antitrust regulations classification  
 of, 124, 129–30  
 Chinese merger controls and, 467–87  
 cooperative commercialization and, 12–16  
 copyright and EU law on, 342–4, 386–7  
 digital single market strategy and EU law on,  
 351–5  
 EU laws concerning, 342–4, 352–3, 386–7  
 ex post regulation and, 54–5  
 future drug product development and, 39–41  
 horizontal merger effects on, 458–62  
 information technology foreclosure of, 455–8  
 inherency in EU case-law concerning, 95–109  
 innovation and, 3–6  
 Internet economics and, 43  
 Japanese antimonopoly protection of, 139–40  
 Korean laws concerning, 158–78  
 merger analysis and, 16–18, 447–50  
 monopoly power and, 215–20  
 net neutrality and, 46–7  
 pharmaceutical mergers and, 39–41  
 in pharmaceuticals industry, 26–39  
 post-expiration royalties and, 238–41  
 prevention of exploitation and, 222–4  
 pro- and anti- aspects of exceptionalism and,  
 97–106  
 product hopping cases and effects of, 38–9  
 reverse payment cases and effects of, 32–8  
 rules-based approach in EU to, 109–10  
 Schumpeterian competition, 49–51  
 static analysis of, 10–12  
 tied products/tying arrangements and EU law  
 on, 404–7  
 in two-sided markets, 44–5  
 Competition Commission of India (CCI),  
 335–6

- competitive harm theory  
 Big Data and, 294–5, 300–10  
 disclosure and deception violations and, 236–8  
 drug patent cases and, 321–2, 331–2  
 market definition and, 188–9  
 network effects on Internet and, 45–6  
 patent assertion entities and, 263–5  
 patent pooling and, 362–3, 369–72  
 payments in drug patent disputes and, 322–4  
 product hopping cases and, 27, 38–9  
 resale price maintenance and, 427–35  
 in Sherman Act, 222–4  
 state law on drug patents and, 331–2  
 tied products and, 362–3, 409–18  
*Walker Process* doctrine and, 277–81
- complementarity  
 bundling and innovation and, 392–4  
 copyright protection and, 198–9  
 defined, 93  
 EU antitrust and intellectual property law and, 106–8  
 exposition and, 106–7  
 in information technology, 388–90  
 in Japanese IP–antitrust intersection, 142–3  
 limits in patent pooling of, 363  
 patent pooling and, 359–63
- compulsory licensing  
 in Chinese IP–antitrust law, 125–6  
 in Chinese patent law, 129–30  
 EU law and, 108–11  
 Japanese IP–antitrust law, 142–3  
 monopoly power and, 216–18  
 rule-based approach to, 110–11
- Concrete Pile* case, 152–3
- conditional rebates, loyalty discounts as, 398–401
- conduct remedies, in merger jurisprudence, 451
- Consten and Grundig v. Commission*, 95–109, 112–15, 342–4
- consumer protection  
 applications of antitrust and, 85–91  
 bargaining power of IT mergers and, 462–4  
 Big Data issues and, 294–6, 310–11  
 Chinese IP–antitrust regulations and, 122, 126–7  
 essential facilities doctrine in Chinese IP–antitrust regulations and, 125–6  
 holdups of patents and, 247–8  
 Internet economics and, 43  
 pharmaceuticals industry and role of, 21–2  
 procompetitive effects of Big Data and, 296–300  
 resale price maintenance and, 429–31  
 reverse payment cases and, 32–8  
 tied products/tying arrangements as threat to, 404–7  
*Walker Process* doctrine and standing of, 277–9  
 welfare effects of intellectual property and, 83–5  
 consumption habit defense, Chinese IP–antitrust regulations and, 126–7
- contractual principles  
 country of origin principle for online transmission and, 349–50  
 EU copyright rules and, 68–9  
 FRAND licensing as, 68–9  
 patent infringement and, 225–9  
 tied products/tying arrangements and, 413–15  
 trade secrets law and, 207–8
- Cooper, James, 294
- cooperative commercialization  
 antitrust policy and, 15–16  
 determinants of innovation prize and, 14–15  
 in Korean IP law, 160–1  
 non-challenge clause in Japanese patent law and, 150–1  
 outcomes of, 13–14  
 rationale for, 12–15
- cooperative licensing agreement, mergers and, 17–18
- coordinated conduct  
 applications of antitrust and, 85–91  
 mergers and, 447–50  
 in Microsoft/Nokia merger case (Korea), 177–8  
 in pharmaceuticals industry, 26–39  
 rule-based approach to cases involving, 112–15
- copyright protection  
 antitrust impact on information technology and, 384–7  
 blanket licensing, 358–9  
 duration of, 211  
 EU bundling and innovation policies and, 386  
 EU digital single market strategy, 339–55  
 European Cable and Satellite Directive and, 344–8  
 EU rules concerning, 341–4, 348–9  
 exhaustion doctrine in EU copyright and, 341–2  
 inherency in EU case-law concerning, 95–109  
 Japanese IP–antitrust policy and, 151–2  
 limits on innovation from, 48–9  
 market definition and, 186–7, 189–91, 198–9  
 monopoly power and, 210  
 phase-out of inherency and, 97–8  
 satellite transmission, 344–5  
 sham litigation doctrine and, 272–3 n.5  
 sufficient economic power principle and, 415–17  
 two-products element in, 411–12  
 country of destination principle  
 European competition law and, 352–3  
*Murphy* case on cable and satellite copyright and, 347–8

- country of origin principle  
 difficulties in identification of, 353 n.64  
 in EC Statement of Objections, 351–2  
 EU copyright rules and, 348–9  
 in *Murphy* case, 345–6  
 for online transmissions, 349–50  
 satellite transmission copyright, 344–5
- country of uplink principle, satellite transmission copyright, 344–5
- Court of Justice of the European Union (CJEU), 92–3  
 coordinated conduct cases and, 112–15  
 digital single market strategy for copyright and, 339–41  
 exceptionalism in EU law and, 98–106  
 operational irrelevance of inherency and, 96–7  
 particularism vs. exceptionalism in cases before, 103–4  
 patent holdup injunctions and, 251–5  
 rule-based approach of, 109–17
- Crane, D.A., 109–10, 397
- cross-border transmission  
 copyright protection and, 344–5  
 country of origin principle and, 349–50  
 digital single market strategy (EU) and, 350–1  
 EU competition law and, 351–5
- cross-elasticity of supply and demand, market definition and, 188–9
- cross-group externalities, in two-sided markets, 44–5
- cross-licensing  
 Japanese IP–antitrust rules and, 153–4  
 Korean IPR guidelines and, 167–8  
 monopoly power and, 219  
 patent pooling and, 358–9  
 rate disclosure and, 61–2
- cross-price elasticities, in two-sided markets, 44–5
- CSIRO v. Cisco*, 74–5
- customer demands, loyalty discounts in Europe and, 400–1
- Czapracka, K., 97–8
- Daiichi-Kosho* (DK) case, 146–7
- damages  
 lost profit damages for patents, 185–6  
 in patent holdups, 255–8  
 for patent infringement, 212  
 for SEP infringement, FRAND provisions for, 73–5
- data-driven defenses, antitrust policy and, 304–5
- Declaratory Judgment Act (DJA) jurisdiction,  
*Walker* Doctrine enforcement and, 279–81
- decoding devices, satellite transmission copyright and, 345–6
- de facto standards, Chinese control of non-SEP related mergers and, 474–6
- de facto standards, Korean IPR guidelines and, 170–1
- de jure standards, Korean IPR guidelines and, 170–1
- delayed entry  
 drug patent settlements and, 319–20, 327–8  
 European investigations of, 332–5  
 horizontal mergers and, 449  
 risk aversion and, 33–4
- Delcamp, Henry, 218–19
- Dell Computers  
 disclosure and deception violations by, 236–8  
 patent ambush by, 249–50
- demand  
 benefit function of innovation and, 3–6  
 for innovation, 205–6  
 Lerner index of monopoly power and elasticity of, 213–14  
 loyalty discounts in Europe and, 400–1  
 merger horizontal transactions and, 447–50  
 monopoly markups and elasticity of, 215–16  
 monopoly power screen and building of, 30  
 pharmaceutical reimbursement policies and, 23–5  
 tied products/tying arrangements and, 410–13  
 welfare consequences of monopolization and, 82–3
- demand-side effects, information technology competitive dynamics, 453–5
- Department of Justice (US)  
 bundling and product integration cases and, 386–7  
 data-driven mergers and defenses and, 304–5  
 horizontal merger jurisprudence and, 458–62  
 Merger Guidelines of, 17–18, 447–50  
 merger jurisprudence and, 446–53  
 merger review process, 452–3  
 patent holdup injunctions and, 251–5
- derivative work right, copyright protection and, 198–9
- design protection  
 disclosure and deception violations and, 236–8  
 in high technology industry, 380–4  
 inherency in EU case-law concerning, 95–109  
 tied products/tying arrangements and, 413–15
- DG Markt, 349–50
- differentiated data, online markets and, 300
- digital lock-in, holdup of patents and, 245–9
- digital single market strategy (DSMS)  
 competition law intervention and, 351–5  
 EU copyright rules and, 339–41  
 proposals for, 350–1

- Dippin' Dots, Inc. v. Frosty Bites Distribution, Inc.*, 196
- direct purchasers, *Walker Process* doctrine and standing of, 277–9
- direct test of monopoly power, monopoly power screen and, 28–32
- disclosure requirements
- exploitation of licensees and, 222–4, 236–8
  - patent ambush as violation of, 249–50
- discount attribution rule
- bundled products discounts and rebates and, 396–7
  - loyalty discounts and, 399–400
- discounting
- of bundled products, 394–8
  - loyalty discounts, 398–401
  - online resale price maintenance and, 431–3
  - in two-sided markets, 44–5
- “dispense as written” principle, 25 n.8
- dispute resolution, FRAND licensing and, 68–9
- distribution
- Big Data and, 298–9
  - copyright protection and, 210
  - European copyright protection and, 342–4
  - monopoly markups and demand elasticity, 215–16
  - resale price maintenance in online markets and, 428–9
  - trademark protection and, 412–13
- Dolby* case, 162–3, 177
- dollar volume effect on commerce, tying arrangements and, 417
- dominance, abuse of
- Big Data impact on, 301–3
  - in Chinese IP–antitrust regulations, 124–5, 222–4, 229–31
  - EU cases involving, 109–11, 231–3
  - exceptionalism in cases of, 102–3
  - holdup of patents and, 251–5
  - Huawei v. InterDigital* case in China and, 131–3, 478–80
  - in Korean IP law, 160–3, 222–4
  - post-expiration royalties and, 240–1
  - resale price maintenance in online markets and, 429–31
  - SAIC Regulation (China) and, 484–5
  - tiered products/tying arrangements as, 404–7
- Dong-A Pharmaceutical Co., 174–5
- double marginalization theory
- in information technology mergers, 388–90
  - royalty stacking and, 70–1
  - US private litigation and government enforcement and, 225–9
- downstream markets
- exploitative abuse of IP and, 222–4
  - Japanese IP–antitrust regulation and, 233–4
  - non-discrimination in FRAND licensing and, 69–70
  - patent assertion entities and, 258–61
- Drake, Keith, 36
- Drexler, J., 92, 106–7
- Dreyfus, C., 97–8
- drug delivery mechanisms, monopoly power screen and, 29–30
- drug marketing and promotion
- product hopping cases and, 38–9
  - reverse payment cases and, 32–8
- drug patents, settlement of disputes involving, 319–36
- Actavis* ruling and, 321–2
  - in Canada, 335–6
  - causation in, 331
  - European settlements, 332–5
  - large and unjustified payment threshold in, 329
  - litigation costs and, 326–7
  - merits of patent principle and, 324–5
  - payment for unrelated services in, 327–8
  - payment issues in, 322–4
  - pleading requirements in, 329–30
  - pre-*Actavis* case-law concerning, 320–1
  - rule of reason in, 326–9
  - state law and, 331–2
  - US patent settlements, 319–32
- DSD case, 102–3, 112
- DSL providers, net neutrality and, 46–7
- duplicative assets, cooperative commercialization and avoidance of, 13–14
- duration of IP protection, 211
- non-durability of Big Data and, 299
- dynamic markets
- antitrust policies and, 3–6
  - established manufacturers safe harbor, RPM litigation, 436–7
  - incumbency advantage and, 3–6
  - in information technology, 445–6
  - information technology competitive dynamics, 453–5
  - innovation and, 3–6, 18–19, 47–9
  - modeling innovation and, 6–10
  - Schumpeterian competition and, 49–51
  - static analysis and, 10–12
- Easterbrook, 49
- Eastman Kodak Co. v. Image Technical Services, Inc.*, 410–13
- eBay court decision, 262
- FRAND licensing and, 73

- e-commerce
  - digital single market strategy (EU) and, 350–1
  - EU digital single market strategy, 339–41
- econometric analysis
  - FRAND licensing balance and, 62–4
  - pharmaceuticals industry and limits of, 25 n.7, 30 n.18
- economic theory
  - antitrust and intellectual property and, 82–5
  - Big Data and, 297–300
  - innovation and, 3–19, 47–52
  - intellectual property and, 83–5, 205–6
  - Internet economics, 43–56
  - Korean intellectual property and competition policies and, 158–9
  - monopoly power and, 212–15
  - resale price maintenance justification based on, 438–9
  - rule-based approach in EU antitrust and avoidance of, 116–17
  - tied products/tying arrangements and, 404–7
- economies of scale
  - Big Data and, 305–8
  - information technology competitive dynamics and, 453–5
  - tied products/tying arrangements and, 404–7
- Edlin, Aaron, 326–7
- effective price concept, European bundled products discounts and rebates guidelines and, 397–8
- effects doctrine
  - Korean Free Trade Commission IPR applications and, 162
  - loyalty discount guidelines in Europe and, 400–1
- efficiency defense
  - mergers and, 450–1
  - resale price maintenance and, 433–4
  - tied products/tying arrangements and, 420–1
- efficient competitor test, European bundled products discounts and rebates guidelines and, 397–8
- Eisenach, Jeffrey A., 51–2, 445–65
- Elhauge, Einer, 70–1, 397
- EMI v. CBS*, 96–7
- Enchelmaier, S., 95
- encryption technology, satellite transmission copyright, 344–5
- enforcement of antitrust and IP laws
  - exceptional circumstances principle and, 98–100
  - in Japan, 140
  - by Korean Free Trade Commission, 160–1
  - mergers and, 16–18
  - in United States, 225–9
  - Walker Process* doctrine and issue of, 279–81
- “Enforcement Perspectives on the *Noerr-Pennington* doctrine” (FTC), 285–7
- Enhanced Patent Quality Initiative, 261–3
- entrant innovation
  - antitrust policy and, 9–10, 15–16
  - cooperative commercialization and, 12–15, 18–19
  - exclusive customer contracts and rate of, 15–16
  - mergers and, 17–18
  - static analysis of, 10–12
- entry barriers
  - Big Data lowering of, 297–8, 305–10
  - Chinese SEPs mergers and role of, 470–4
  - innovation and antitrust policies and, 3–6
  - market definition in antitrust and, 188–9
  - tied products/tying arrangements as tool for, 404–7
- entry dates
  - holdup of patents and, 59–62
  - instantaneous vs. delayed entry, 33–4
  - in reverse payment cases, 27 n.12
  - reverse payment cases and, 32–8
- equilibrium rate of innovation, 8–9
- equivalence principle, *Walker Doctrine* enforcement and, 279–81
- Erauw-Jacquery v. La Hesbignonne*, 115
- Ericsson v. D-Link Systems*, 251–5
- error-cost framework
  - limits to innovation and, 49
  - Schumpeterian competition and, 50–1
- E.R.R. Presidents Conference v. Noerr Motor Freight, Inc.*, 281–8
- essential facilities doctrine
  - Chinese IP–antitrust regulations and, 125–6
  - information technology and role of, 390–1
- essential function principle
  - EU antitrust and intellectual property policy and, 94–8
  - inherency and, 97–106
  - in *Samsung Electronics* case, 176
  - tied products/tying arrangements and, 410–13
- Essential Patent Claims, 74–5
- European Commission (European Union)
  - antitrust and intellectual property in law of, 92–117
  - Big Data cases and, 308–10
  - bundled products discounts and rebates and, 397–8
  - bundling and information technology and antitrust policies in, 386
  - Cable and Satellite Directive, 344–8
  - competition law and copyright in, 342–4

- complementarity antitrust and intellectual property law in, 106–8
- coordinated conduct cases in, 112–15
- copyright rules in, 341–4, 348–9
- data-driven mergers in, 304–5
- digital single market strategy, copyright licensing, 339–41, 350–1
- drug patent settlements in, 332–5
- emergence of inherency in case-law of, 95–109
- essential facilities doctrine in, 390–1
- exceptionalism in antitrust and intellectual property policy and, 98–106
- GE/Honeywell merger opposed by, 388–90
- high tech design protection cases in, 380–4
- inherency in antitrust and intellectual property policy of, 94–8
- license pricing and terms in IPR policy, 112
- loyalty discounts in bundled products guidelines, 398–401
- patent holdup injunctions and, 251–5
- product design protection in, 380–4
- regulatory context of competition law in, 352–3
- remedy for IPR, cases involving, 111–12
- resale price maintenance rules in, 425 n.1
- rule-based approach to antitrust-IP intersection and, 109–17
- European Court of Justice (ECJ), 341–2
  - loyalty discounts and rulings by, 400–1
  - Murphy* case and, 345–8
- European Telecommunications Standards Institute (ETSI)
  - FRAND licensing and, 62–4
  - Huawei v. InterDigital* case in China and, 131–3
  - UMTS standard, 60, 225 n.10
- Evans, D.S., 3–6, 10–12, 16–18, 50–1, 384–7
- event study research, reverse payments cases and, 36–8
- ex ante rules
  - complementarity theory and, 93
  - Internet regulation and, 54–5
  - patent disclosure and deceptive practices and, 64–7
  - rule-based approach to intellectual property and, 109–10
- exceptionalism, theory of
  - antitrust law and, 102–3
  - complementarity as rejection of, 106–7
  - defined, 92–3
  - EU antitrust and intellectual property cases and, 98–106
  - lack of specificity concerning intellectual property rights, 102
  - limits of, 105
  - open-ended content of, 104–5
  - opposition in EU courts to, 102–5
  - particularism and, 103–4
  - pro- and anti- aspects of, 97–106
  - refusal to license cases and, 98–100
  - support in EU for, 101–2
- excessive pricing
  - Chinese litigation involving, 229–31
  - disclosure and deception violations and, 236–8
  - European litigation concerning, 231–3
  - FRAND obligations and, 224–35
  - Japanese litigation concerning, 233–4
  - Korea Free Trade Commission investigation of, 234–5
  - US litigation and enforcement involving, 225–9
- exclusionary practices
  - antitrust and, 18–19
  - in Chinese IP–antitrust regulations, 126–7
  - disclosure requirements and deception and, 236–8
  - exclusion payment, in reverse payment cases, 32–8
  - information technology foreclosure of competition and, 455–8
  - network effects on Internet and, 45–6
  - patent pooling and, 369–72
  - SAIC Regulation (China) concerning, 484–5
  - in US antitrust law, 222–4
- exclusive customer contracts
  - antitrust policy and, 15–16
  - loyalty discounts and, 399–400
- exclusive rights
  - EU exceptionalism and exercise of, 101–2
  - Murphy* case on cable and satellite copyright and, 347–8
- exclusive-supply contracts, loyalty discounts and, 399–400
- exercise of right, in Japanese IP–antitrust law
  - establishment of, 143–4
  - output and price restrictions and, 148
  - restrictive licenses and, 147–51
  - tying and package licensing and, 149–50
  - unilateral refusal to license and, 146–7
- exhaustion doctrine
  - cable and satellite copyright and, 347–8
  - EU copyright licensing and, 341–2
  - Japanese IP–antitrust law, 142–3
  - market definition and, 201
- existence v. exercise dichotomy
  - EU antitrust and intellectual property policy and, 94–8
  - inherency in EU case-law and, 95–109
  - phase-out in EU case-law of, 97–8

- exoneration, rule, EU IPR remedy cases and, 111–12
- expert analysis, FRAND licensing and, 58–9
- expired or exhausted patents. *See also* post-expiration royalties
- exploitation of post-expiration royalties and, 238–41
- Japanese IP–antitrust law concerning, 148–9
- Korean *Qualcomm* case involving, 173–4
- post-expiration royalties, 222–4
- exploitative abuse
- applications of antitrust and, 85–91
- Chinese litigation involving, 229–31
- disclosure violations and deception as, 236–8
- excessive pricing as, 224–35
- future challenges in antitrust law concerning, 241–2
- of intellectual property, 222–42
- in US antitrust law, 222–4
- ex post regulations
- complementarity theory and, 93, 106–8
- FRAND licensing and, 66–7
- Internet economics and, 54–5
- rule-based approach to EU antitrust and, 116–17
- express collusion, pooling of patents and, 368–9
- extra-territoriality
- country of origin principle for online transmission and, 349–50
- EU copyright law and, 342–4, 348–9
- in *Murphy* case, 345–6
- pay TV operators in EU and, 351–2
- Ezrachi, Ariel, 302
- Facebook, WhatsApp merger with, 308–10
- Fair, Reasonable and Non-Discriminatory (FRAND) licensing
- balance in policies of, 62–4
- business model of SEPs and, 73
- Chinese IP–antitrust regulations and, 127–9, 229–31
- Chinese merger remedies involving, 473–4
- damages for SEP infringement, 73–5
- disclosure and deceptive violations and, 238
- dispute resolution and, 68–9
- emphasis on fair and reasonable in, 64–7
- EU litigation involving, 111–12, 231–3
- evolution of interpretations of, 64–71
- exceptionalism and particularism concerning, 103–4
- excessive pricing and obligations of, 224–35
- exploitative abuse issues and, 222–4, 241–2
- holdup of patents and, 247, 250–8
- Huawei v. InterDigital* case in China and, 131–3, 478–80
- impetus for, 59–62
- injunctions as tool for, 71–2, 251–5
- Japanese litigation concerning, 233–4
- Korean IP and competition policies and, 158–9, 168–9, 173–4, 234–5
- litigation of SEPs and, 71–5
- in Microsoft/Nokia merger case (Korea), 177–8
- non-discrimination prong of, 69–70
- patent ambush cases and, 249–50
- patent assertion entities and, 263–5
- patent pooling and, 372
- post-expiration royalties and, 238–41
- royalty stacking and, 70–1
- in *Samsung Electronics* case, 176
- sham litigation doctrine and, 288–92
- standard setting organizations and, 58–9, 168–9, 219–20, 224–5
- US private litigation and government enforcement and, 225–9
- fair use. *See also* usage
- copyright protection and, 210
- market definition and, 187
- Farrell, Joseph, 65–6
- Federal Communications Commission (FCC)
- AT&T–T-Mobile merger and, 458–62
- on bargaining power of mergers, 462–4
- Internet regulation and, 53
- merger remedies and, 451
- merger review process, 452–3
- net neutrality and, 53–4
- regulatory authority of, 56
- Federal Trade Commission (US) (FTC)
- Big Data cases and, 308–12
- Dell computers case and, 249–50
- disclosure and deception violations and, 236–8
- drug patent settlements and, 320–1
- established manufacturers safe harbor, RPM litigation, 436–7
- FRAND licensing and, 58–9, 227
- horizontal mergers and, 460–1
- Japanese IP–antitrust policies compared with, 233–4
- merger jurisprudence and, 446–53
- merger review process, 452–3
- monopoly power screen and direct test of, 28–32
- patent ambush cases and, 64–7
- patent assertion entities and, 260–2
- reverse-payment drug patent settlements and, 319–20
- sham litigation doctrine and, 285–7, 290–1
- feedback loops, Big Data management and, 294, 305–8
- field of use restriction, Japanese law on, 147–51
- First, Harry, 222–42

- First Amendment rights, sham litigation doctrine and, 287–8
- first consent principle, in Microsoft/Nokia merger case (Korea), 177–8
- first sale doctrine. *See* exhaustion doctrine
- Fisher, Franklin, 10–11, 47–9
- fixation condition, copyright protection and, 210
- fixed fees, in two-sided markets, 44–5
- Food and Drug Administration (FDA)  
 “authorized generics” and, 322–4  
 brand and generic drug approval, 22–3, 25–6  
 labeling of drugs by, 30–1  
 patent litigation and, 286  
 pharmaceuticals industry and, 21–2
- Football Association Premier League Ltd. (FAPL)*  
 case, 112–15
- foreign enterprises, Korean Free Trade Commission IPR applications for, 162
- formularies  
 monopoly power screen and role of, 31  
 in pharmaceuticals industry, 23–5
- Framework Act on Intellectual Property (Korea), 160
- franchises, trademark protection and, 412–13
- FRAND licensing. *See* Fair, Reasonable and Non-Discriminatory (FRAND) licensing
- fraudulent intent, *Walker Process* doctrine and claims of, 274–7
- free competition, reducing, in Japanese antimonopoly laws, 141–2
- free riding behavior  
 new entrants safe harbor, RPM litigation, 437–8  
 resale price maintenance as, 427–31
- FTC v. Actavis*, 261–2, 321–2. *See also* *New York v. Actavis* case  
 litigation cost issues in, 326–7  
 merits of patent issue in, 324–5  
 patent pooling and collusion in, 368–9  
 payment for unrelated services in, 327–8  
 payment issues in, 322–4
- FTC v. Cephalon, Inc.*, 276–7, 324–5, 327–8
- FTC v. Rambus*, 61, 64–7. *See also* *Hynix Semiconductor Inc. v. Rambus Inc.*; *Rambus, Inc. v. Infineon Techs, AG*
- FTC v. Watson Pharmaceuticals*, 320–1
- functional remedies, in Chinese merger litigation, 476–8
- future competition, horizontal mergers and, 461
- future profits of innovation  
 determinants of, 7–9  
 net present value, 205–6
- future rate of innovation, incumbency advantage and, 3–6
- Gans, Joshua S., 3–19
- gatekeeping practices, in pharmaceuticals industry, 21–2
- GE/Honeywell merger, 388–90
- Genentech Inc. v. Hoechst GmbH*, 115
- General Electric, Shenhua Group joint venture with, 474–6
- generic drugs  
 “authorized generics,” 322–4  
 European patent settlements and, 332–5  
 FDA approval of, 22–3  
 Korean GSK anticompetitive patent decision and, 174–5  
 litigation costs in defense of, 326–7  
 market definition and, 189–91  
 monopoly power screen and, 28–32  
 payment for unrelated services in settlements involving, 327–8  
 payment issues in drug patent settlements and, 322–4  
 product hopping cases and, 38–9, 87–9  
 regulations governing, 25–6  
 reverse payment cases and, 26–7, 38–9, 89–90, 319–20
- geo-blocking. *See also* block-booking practices  
 copyright protection and, 339–41  
 digital single market strategy (EU) and, 350–1  
 European competition law and, 352–3
- Georgia Pacific Corp. v. U.S. Plywood Corp.*, 67
- Gifford, David, 379–401
- Gilbert, Richard, 69–70, 365
- Gilead Sciences, 215–16
- Gilliam, Terry, 209–10
- Ginsburg, Douglas H., 326–7
- GlaxoSpain* case, 342–4
- good will defense, tied products/tying arrangements and principle of, 418–20
- Google  
 AdMob acquired by, 461  
 DoubleClick acquisition by, 304–5, 308–10  
 European litigation involving, 231–3  
 FTC investigation of, 227, 233–4  
 ITA Software acquisition by, 458
- Google/Motorola* merger (China), 470–4
- grantbacks in patent law  
 China IP–antitrust case-law concerning, 127–9, 133–5  
 Japanese IP–antitrust law and, 150
- Greenfield, Leon, 271–92
- Greenlee, Patrick, 397
- Green Paper of the European Commission. *See also* Cable and Satellite Directive (EU)  
 on EU copyright rules, 348–9

- GSK anticompetitive patent decision, Korean ISP law and, 174–5
- GSK v. *Commission* case, 112–15
- Guidelines for Patent and Knowhow Licensing Agreements (Japan), 142–3
- Guidelines for the Use of Intellectual Property under the Antimonopoly Act (Japan), establishment of, 138
- Gundlach, Gregory, 430–1
- Handgards, Inc. v. Ethicon, Inc.*, 282–3
- Handgards* doctrine  
 basic principles of, 271–2  
 improper patent assertion and, 288–92  
 litigation costs as antitrust injury in, 272  
 sham petitioning activity and, 282–3
- Hartford-Empire* case, 371–2
- Hart-Scott-Rodino Antitrust Improvements Act, 452–3
- Hatch-Waxman litigation, 326–7
- Hazlett, T.W., 49
- Hemphill, Scott, 326–7
- Henry v. A.B. Dick Co.*, 407–13
- Herfindahl-Hirschman Index (HHI), 447–50
- Heyer, Ken, 386–7
- high technology. *See* information technology
- Hoechst Marion Roussel* case, drug patent settlement in, 320–1
- Hoffmann-LaRoche v. Centrafarm*, 95–109
- Hokkaido Press* case, 145
- holdup of patents. *See also* licensee holdout  
 damages as factor in, 255–8  
 in FRAND disputes, 250–8  
 future challenges concerning, 265–6  
 injunctions for, 71–2, 251–5  
 leveraging of royalty payments with, 59–62  
 in Microsoft/Nokia merger case (Korea), 177–8  
 overview of litigation concerning, 245–66  
 patent ambush and, 64–7  
 by patent assertion entities, 247, 258–65  
 patent pooling and avoidance of, 360  
 poor patent quality and, 261–3  
 reverse holdup/holdout theories and, 62–4  
 royalty stacking and, 70–1  
 in standard-setting context, 249–58  
 US litigation and enforcement involving, 227–9
- Horizontal Cooperation Guidelines (European Commission), 231–3
- horizontal mergers  
 bargaining power of, 462–4  
 Chinese SEPs mergers as, 470–4  
 competitive effects of, 458–62  
 US jurisprudence concerning, 447–50
- Hovenkamp, E., 358–73, 393–4, 417–18, 438–9
- Hovenkamp, H., 48–9, 52, 293–313, 326–7, 358–73, 393–4
- Huawei v. InterDigital* case, 131–3, 229–31, 256–7, 478–80
- Huawei v. ZTE* case, 103–4, 107–8, 111–12, 251–5
- Hylton, Keith N., 81–91
- Hynix Semiconductor Inc. v. Rambus Inc.*, 288–92.  
*See also* *FTC v. Rambus*; *Rambus, Inc. v. Infineon Techs, AG*
- hypothetical monopolist test, merger horizontal transactions and, 447–50
- IBM  
 bundling and innovation at, 393  
 product design protection and, 380–4, 386–7
- IBM v. United States*, 418–20
- Illinois Tool Works Inc. v. Independent Ink, Inc.*, 87, 124–5, 416–17
- Image Technical Services v. Eastman Kodak*, 125–6
- immunity from antitrust  
 Internet providers, implied immunity of, 56  
*Noerr-Pennington* doctrine, 273  
 sham litigation doctrine and, 281–8  
 “improvement” patents, 361–2
- IMS Health* case, 98–105, 110–11, 386, 391
- incentive theory of copyright, 210
- incremental value principle, FRAND licensing and, 65–6
- incumbency  
 accelerated product development and, 16  
 antitrust policy impact on, 9–10  
 cooperative commercialization and, 12–15  
 exclusive customer contracts and, 15–16  
 innovation and antitrust policies and, 3–6  
 innovation prize and, 7–9  
 mergers and, 17–18  
 net neutrality and, 46–7  
 network effects on Internet and, 45–6  
 Schumpeterian competition and, 49–51  
 static analysis of, 10–12
- India  
 drug patent settlements in, 335–6  
 exploitative abuse of IP in laws of, 222–4  
 indirect network effects, in two-sided markets, 44–5
- infant industries defense, tied products/tying arrangements and, 420
- information technology  
 bargaining power of mergers in, 462–4  
 Big Data regulation and, 293–313  
 blocking of patents in, 361–2  
 bundled products and antitrust in, 379–401  
 Chinese merger litigation concerning, 476–8  
 competition foreclosure, incentive and ability for, 455–8

- competitive market dynamics of, 453–5  
 conduct remedies concerning antitrust in, 451  
 discounts and rebates on bundled products and, 394–8  
 double marginalization, efficiencies, and portfolio effects in, 388–90  
 FRAND licensing and, 224–5  
 holdups of patents and, 245–9  
*Huawei v. InterDigital* case in China and, 478–80  
 limits of antitrust involving, 384–7  
 merger review process for, 452–3  
 mergers in, 445–65  
 net neutrality and, 53–4  
 product design and, 380–4  
 Schumpeterian competition and, 49–51  
 tied products/tying arrangements and, 404–7
- InfoSoc Directive, 341–2
- infringement litigation  
 European “infringement by object” principle, 332–5  
 market definition and, 200–1  
 misuse doctrine and, 409  
 patent assertion entities use of, 258–61  
 patent protection and, 206–7  
 remedies and investment incentives and, 212  
*Walker Process* doctrine and, 273–4
- inherency, theory of  
 defined, 92  
 in EU antitrust and intellectual property, 94–8  
 exceptionalism compared with, 97–106  
 formative EU case-law on, 95–109  
 operational irrelevance, 96–7  
 phase-out in EU case-law of, 97–8
- injunctions for patent infringement  
 copyright protection and, 210  
 FRAND licensing and, 71–2  
 holdups of patents and, 247–8, 251–5  
 in Korean IPR guidelines, 169  
 patent assertion entities and, 262  
 trade secrets law and, 207–8
- innovation  
 antitrust law as limit on, 47–9, 384–7  
 Big Data impact on, 296–7, 301–3  
 in broadband markets, 51–2  
 bundled products and, 392–4  
 Chinese IP–antitrust regulations and, 122  
 costs of incumbency and, 8–9  
 dynamics modeling, 6–10  
 essential facilities doctrine in Chinese IP–antitrust regulations and, 125–6  
 horizontal merger impact on, 458–62  
 incentivization of, 83–5  
 intellectual property law as limit on, 47–9  
 in Japanese antimonopoly laws, 139–40  
 Korean IP law and protection of, 163  
 mergers’ impact on, 16–18, 450  
 patent assertion entities and, 258–61  
 patent pooling and rates of, 372–3  
 in pharmaceuticals industry, 21–2  
 post-expiration royalties and, 238–41  
 Schumpeterian competition and, 49–51  
 size of prize of, 7–9  
 tied products/tying arrangements impact on, 404–7
- innovation economics  
 antitrust/intellectual property limits on  
 innovation and, 47–9  
 Internet and, 47–52  
 net present value and, 205–6  
 theory of, 3–19
- In re Aggrenox Antitrust Litigation*, 329–30  
*In re Buspirone Patent Litig./In re Buspirone Antitrust Litig.*, 286  
*In re Cardizem CD Antitrust Litigation*, 320–1  
*In re Cipro Cases I & II*, 331–2  
*In re Ciprofloxacin Hydrochloride Antitrust Litigation*, 320–1  
*In re DDAVP Direct Purchase Antitrust Litig.*, 277–9  
*In re Effexor XR Antitrust Litigation*, 329  
*In re K-Dur Antitrust Litigation*, 320–1  
*In re Lamictal Direct Purchaser Antitrust Litigation*, 329  
*In re Lipitor Antitrust Litigation*, 329–30  
*In re Loestrin 24 FE Antitrust Litigation*, 329  
*In re Niaspan Antitrust Litigation*, 331  
*In re Robert Bosch* case, 251–5, 291 n.110  
*In re Tamoxifen Citrate Antitrust Litigation*, 320–1
- Institute of Electrical and Electronics Engineers (IEEE)  
 FRAND licensing and, 61–2  
 IPR policy of, 71–5  
 patent holdup injunctions and policy update of, 251–5
- institutional culture, in pharmaceuticals industry, 21–2
- Insung Industry* case, 172–3
- integration of products. *See also* interoperability standards; technology transfer agreements  
 design protection and, 380–4  
 limits of antitrust principles concerning, 384–7  
 Microsoft lawsuits and level of, 10–12, 380–4
- Intel Corporation, disclosure and deception violations by, 236–8
- Intellectual Property Basic Act (Japan), 142–4

- intellectual property law/intellectual property rights (IPL/IPR)  
 abuse of dominance cases, 109–11  
 additional abusive conduct principle and, 108–9  
 Anti-Monopoly Law in China and, 121–9  
 antitrust and, 18–19, 81–91  
 in China, 120–36, 467–8, 478–86  
 complementarity in EU concerning, 106–8  
 complementarity in Japanese law on, 142–3  
 coordinated conduct cases in EU and, 112–15  
 copyright protection in Europe and, 342–4  
 duration of protection, 211  
 economics of, 83–5, 205–6  
 essential facilities doctrine in EU law and, 390–1  
 European law and, 92–117, 342–4, 352–3  
 European Telecommunications Standards Institute policies and, 62–4  
 exceptionalism in EU concerning, 98–106  
 exemptions in Japanese law concerning, 143–4  
 exploitative abuses of, 222–42  
 FRAND licensing commitment to, 59–62  
 history of tying arrangements and, 407–9  
 information technology and limits of, 384–7  
 innovation collaboration and, 52  
 in Japan, 138–55  
 Japan Fair Trade Commission “General Designation” and, 141–2  
 Korean laws concerning, 158–78  
 legitimate business defenses in violation of, 418–21  
 license pricing and terms and, 112  
 limits to innovation and, 47–9  
 litigation costs and, 326–7  
 market definition and, 185–91, 196–201  
 market miscalculation in, 194  
 monopoly power and, 204–20  
 in pharmaceuticals, 21–41  
 pro- and anti- aspects of exceptionalism and, 97–106  
 refusal to license cases, 110–11  
 remedies and investment incentives, 111–12, 212  
 rule-based approach to, 109–17  
 SAIC Regulation (China) and, 483–6  
 sufficient economic power principle and, 415–17  
 tied products and, 404–22  
*Intellectual Ventures I LLC v. Capital One Fin. Corp.*, 262–5  
 intent, in *Walker Process* doctrine, 275–7  
 interbrand/intrabrand competition, market definition and, 184, 192–4  
 InterDigital corporation, 131–3  
 Interim Provisions on the Administration of National Standards Involving Patents (China), 128  
 intermediary platform, Internet two-sided markets and, 43–7  
*International Salt* case, 409, 415–21  
 International Technology Transfer Guidelines, 142–3  
 Internet. *See also* online markets  
 broadband innovation and, 51–2  
 Chinese laws concerning, 129–31  
 data differentiation on, 300  
 design protection and development of, 380–4  
 economics of, 43–56  
 ex post regulation of, 54–5  
 holdups of patents and innovation on, 245–9  
 implied immunity from antitrust and, 56  
 innovation economics on, 47–52  
 net neutrality and, 46–7  
 nonexclusive/nonrivalrous content on, 299  
 regulation and economics of, 52–6  
 Schumpeterian competition and, 49–51  
 streaming, EU transmission copyright and, 353 n.64  
 tied products/tying arrangements and, 404–7  
 two-sided markets and network effects of, 43–7  
 “Internet of Things,” holdups of patents and, 245–9  
 Internet Service Providers (ISPs)  
 Chinese regulation of, 130–1  
 as multi-homing agent, 44–5  
 net neutrality and, 53–4  
 interoperability standards  
 design protection and, 380–4  
 FRAND licensing and, 59–62, 224–5  
 holdup of patents and, 245–9  
 monopoly power and, 219–20  
*inter partes* review, patent assertion entities and, 262–3  
 Interpretation of the Internet Rules (MIIT Interpretation) (China), 129–31  
 Investigative New Drug (IND) applications, 22–3  
 investment in innovation  
 antitrust impact on information technology and, 384–7  
 holdup of patents and, 245–9  
 incentives in IP for, 212  
 net present value and, 205–6  
 patent assertion entities and, 258–61  
 investors in pharmaceuticals, reverse payment settlements as reward for, 36–8  
 IFA Software, Google acquisition of, 458  
*ITT Promedia* case, 102  
 Japan  
 complementarity in IP–antitrust law of, 142–3  
 excessive pricing litigation in, 233–4  
 future IP–antitrust issues in, 155

- intellectual property and antitrust in, 138–55  
 non-challenge clause in patent law of, 150–1  
 patent and trademark application in, 145  
 patent infringement lawsuits in, 145–6  
 research and development restrictions in, 151  
 restrictive licenses regulations in, 147–51  
 royalty payment and calculation policies in, 151–2  
 tying and package licensing in, 149–50  
 unilateral refusal to license in IP–antitrust law of, 146–7
- Japanese Society for Rights of Authors, Composers and Publishers (JASRAC), 151–2
- Japan Fair Trade Commission (JFTC)  
 Antimonopoly Law (AML) Article 3 and, 139–40  
 Antimonopoly Law (AML) Article 19 and, 141–2  
 complementarity in rulings by, 142–3  
 FRAND licensing obligations and, 233–4  
 guidelines of, 138  
*Microsoft (NAP)* case and, 153–4  
*Microsoft (Tying)* case and, 149–50  
 patent and trademark application, 145  
 resale price maintenance rulings and, 148–9  
*Twentieth Century Fox Japan (TCFJ)* case and, 148
- Japan Patent Office (JPO), 145
- Javico* case, 342–4
- JEDEC standards body, 64–7
- Jefferson Parish Hospital No. 2 v. Hyde*, 126–7, 384, 389–90, 410–13, 418–20
- joint conduct  
 applications of antitrust and, 85–91  
 FRAND licensing negotiations and, 67  
 patent pooling and, 359–63, 371  
 in pay-for-delay and reverse payment cases, 26–7  
 royalty stacking and, 70–1
- judicial economy principle, rule-based approach in EU antitrust and, 116–17
- Kahn, Alfred, 54–5
- Kaplow, Louis, 84–5, 195
- Katz, M.L., 49–51
- Kimble v. Marvel Entertainment*, 87, 127, 238–41
- King Drug Company of Florence v. Smithkline Beecham Corporation (Lamictal)*, 322–4
- Kirkwood, John, 425–40
- Klein, Benjamin, 429–33
- knowledge, imputation of, in *Walker Process* doctrine, 275–7
- Kobayashi, Bruce H., 326–7
- Kobe, Inc. v. Dempsey Pump Co.*, 290
- Kobec* case, 172
- Korah, V., 116–17
- Korea  
 cases of IPR abuse in, 171–8, 222–4  
 competition law and intellectual property in, 158–78  
 drug patent settlements in, 335–6  
 future of IPA abuse regulation in, 178  
 KFTC IPR guidelines and, 161–71  
 post-expiration royalties cases in, 240–1
- Korea Intellectual Property Office (KIPO), 160
- Korean Fair Trade Commission (KFTC)  
 anticompetitive patent dispute agreements and, 169–70  
 cases of IPR abuse and, 171–8  
 cooperation with government IP agencies, 160  
 determination of illegality by, 163  
*Dolby* unfair licensing practices case and, 177  
 drug patent settlements, 335–6  
 enforcement activities of, 158–9  
 GSK anticompetitive patent decision, 174–5  
 IPR abuse guidelines, 161–71  
 licensing terms in IPR guidelines, 164–7  
*Microsoft/Nokia* merger and, 177–8  
 Monopoly Regulation and Fair Trade Act regulations and, 162–3  
 nonpracticing entities patent rights, 170  
 patent pooling and cross licensing and, 167–8  
 patent rights guidelines, 163–4  
 post-expiration royalties cases and, 240–1  
 proposed amendments to IPR guidelines, 170–1  
*Qualcomm* case and, 173–4  
*Samsung Electronics* SEP abuse case, 176  
 scope of application, 162  
*SK Telecom* unfair licensing practices and, 175  
 standards-based approach to intellectual property and, 168–9  
 structure and activities of, 159–60
- Krehl v. Baskin-Robbins Ice Cream Co.*, 412–13
- Kudrle, Robert T., 379–401
- Lambrecht, Anja, 297–300
- Lampe, Ryan, 218–19
- Lang, Temple, 108–9
- language, in tied products/tying arrangements litigation, 410–13
- Lao, Marina, 427–8, 431–3
- large and unjustified payment threshold, in drug patent settlements, 329
- Larouche, Pierre, 68–9
- Layne-Farrar, Anne, 58–75
- Lear v. Adkins, Inc.*, 127
- Lee, Hwang, 158–78
- Leegin* case, 425–7

- legality principle  
 determination of illegality in Korean IP law and, 163  
 discount attribution rule and, 396–7  
 EU coordinated conduct cases and, 115  
 legal uncertainty, rule-based approach to intellectual property and, 116–17  
 legitimate expectations principle, patent holdup injunctions and, 251–5  
 Lemley, Mark A., 68–9, 183–202  
 LePage's Inc., 394–8  
 Lerner, Abba, 213–14  
 Lerner, Andres, 294, 305–8  
 Lerner, Josh, 62–4, 218–19  
 Lerner index of monopoly power, 213–14  
 information technology competitive dynamics and, 453–5  
 Les Laboratoires Servier, 332–5  
 Leslie, Christopher R., 279–81, 404–22  
 leverage theory  
 applications of antitrust and, 87  
 holdup of patents and, 245–9  
 product hopping cases and, 87–9  
 royalty holdups and, 59–62  
 tied products/tying arrangements and, 404–7  
 liability  
 production integration cases and, 383  
 rule-based approach to intellectual property and, 109–12, 116–17  
 licensee holdout, SEP holders and, 62–4  
 licensees, in patent pooling, 363  
 licensing. *See also* cross-licensing; grantbacks in patent law; package licensing; tied products/tying arrangements; unfair trade practices  
 Chinese IP–antitrust regulations and, 125–7, 229–31  
 in Chinese Patent Law, 129–30  
 compulsory licensing, 108–9  
 copyright, EU competition law and, 341–4  
 disclosure requirements and deception concerning, 236–8  
 EU digital single market strategy and, 339–55  
 exceptionalism in refusal to license cases, 98–100  
 FRAND licensing, 58–75  
 “holdups” to leverage royalty payments, 59–62  
 innovation and, 14–15  
 IPR license pricing and terms, 112  
 Japanese IP agreements concerning, 152–3  
 Korean IPR abuse case-law and, 171–8  
 Korean IPR guidelines and, 164–7  
 Korean limitations on scope of, 165–6  
*Murphy* case on cable and satellite copyright and, 347–8  
 patent assertion entities and, 258–61  
 patent pooling and, 359–63  
 post-expiration royalties and economics of, 238–41  
 restrictive licenses regulations in Japan, 147–51  
 territorial licensing, cable and satellite transmission copyright, 345  
 unilateral refusal to license, Japanese IP–antitrust laws and, 146–7  
 likelihood of confusion test, trademark registration and, 199–200  
 Lim, Daryl, 245–66  
 limited-license theory, in EU antitrust and intellectual property, 92 n.1  
 limited period of protection, Japanese IP–antitrust law, 142–3  
*Line Materials* case, 361–2, 368–9  
 litigation costs  
 as antitrust injury, 272 n.4  
 rule of reason in drug patent settlements and, 326–9  
*Litton Systems v. Am. Tel. & Tel. Co.*, 285–7  
 Liyang Hou, 467–87  
 Llobet, Gerard, 65–6, 73–5  
*Loewe's* case, 415–17  
 long-term therapies, monopoly power screen and, 31–2  
 loss of quality theory, Big Data and, 301–3  
 lost profit damages, market definition and, 185–6  
 “lottery-ticket” patent assertion entities, 260–1  
 loyalty discounts, for bundled products, 398–401  
*Lundbeck* case, 102–3  
 Lundbeck Company, 332–5  
*Magill* case, 97–106, 110–11, 116–17, 390–1  
 Manne, G.A., 49  
 Manning, Kenneth C., 430–1  
 manufacturers  
 online resale price maintenance impact on, 427–34  
 safe harbor for, in resale price maintenance, 436–7  
 marginal cost of production  
 antitrust impact on information technology and, 384–7  
 Big Data creation and, 298–9  
 Lerner index of monopoly power and, 213–14  
 market definition and, 194  
 monopoly markups and demand elasticity, 215–16  
 patent pooling exclusivity and, 369–72  
 welfare consequences of monopolization and, 82–3  
 Mariniello, Mario, 66–7  
 market-by-market assessment, pharmaceutical mergers and, 39–41

- market definition/market power. *See also* two-sided markets
- antitrust and, 85–91, 188–9
  - Big Data and, 310
  - boundary delineation in patent pooling and, 365–6
  - broadband innovation and, 51–2
  - bundling and innovation and, 392–4
  - case-law on IP and, 192–4
  - Chinese control of non-SEP related mergers and, 474–6
  - Chinese IP–antitrust regulations and, 122–3
  - Chinese merger control and assessment of, 472–3
  - copyright protection and, 186–7, 189–91, 198–9
  - design protection cases and, 384
  - in drug patent cases, 321–2
  - established manufacturers safe harbor, RPM litigation, 436–7
  - exhaustion and first sale doctrines, 201
  - FRAND licensing and, 61
  - future challenges for, 201–2
  - holdup of patents and, 248–9
  - horizontal transactions in mergers and, 447–50
  - implicit definition and, 187–8
  - information technology and antitrust policy and, 384–7
  - information technology competitive dynamics, 453–5
  - injunctions on patent infringement and, 71–2
  - innovation and, 3–6
  - intellectual property doctrine and, 185–91, 196–201
  - Japanese antimonopoly protection of, 139–40
  - in Korean I/P law, 158–9, 162–3
  - limitations of, 194–6
  - merger horizontal transactions and, 447–50
  - Microsoft lawsuit and, 10–12
  - miscalculation in IP of, 194
  - monopoly power and, 215
  - net neutrality and, 53–4
  - overview of, 183–202
  - patent ambush and, 64–7
  - patent assertion entities and, 263–5
  - patent pooling and, 367–72
  - in pharmaceuticals industry, 21–2
  - product differentiation and, 188–94
  - Qualcomm* case in China and, 480–1
  - rate of innovation and, 3–6
  - regulatory limits to innovation and, 47–9
  - resale price maintenance in online markets and, 427–8, 435
  - scope of patent rights and, 200–1
  - standard essential patents and, 471–2
  - sufficient economic power principle and, 415–17
  - trademark registration and, 185, 199–200
- market share
- information technology foreclosure of competition and, 455–8
  - innovation and antitrust policies and role of, 4–5
  - Japanese antimonopoly protection of, 139–40
  - loyalty discounts for bundled products and, 398–401
  - merger horizontal transactions and, 447–50
  - Schumpeterian competition and, 49–51
- Masimo Corp. v. Tyco Health Care Group*, 398–401
- Mattel* suit, 186–7
- McDonough* case, 429–31
- MCI v. AT&T*, 125–6
- McKenna, Mark P., 183–202
- Measures for Compulsory Licensing of Patent Implementation (China), 129–30
- media rating services, horizontal mergers of, 460–1
- medical best practices, off-label drug use and, 300–1 n.17
- MedImmune* test, *Walker* Doctrine enforcement and, 279–81
- Mediplorer* case, 148–9
- Merck KGaA–AZ Electronics merger, 474–6
- Mercoid Corp.* case, 409
- mergers
- antitrust impact on, 13, 16–18
  - bargaining power of IT mergers, 462–4
  - Chinese IPR and control of, 467–87
  - data-driven defenses of, 304–5
  - efficiencies in, 450–1
  - Facebook/WhatsApp merger, 308–10
  - holdup of patents and, 256–7
  - horizontal mergers, 447–50
  - horizontal transactions and, 447–50
  - as industry maneuvers, 18–19
  - information technology competitive dynamics and, 453–5
  - in information technology sector, 445–65
  - IPR-related abuses in China and, 478–86
  - market definition and, 195
  - Microsoft/Nokia merger case (Korea), 177–8
  - non-SEP related mergers, Chinese control of, 474–8
  - in pharmaceuticals industry, 39–41
  - portfolio effects doctrine and, 388–90
  - remedies in jurisprudence on, 451
  - review process for, 452–3
  - SEPs-related mergers in China and, 470–4
  - US jurisprudence concerning, 446–53
  - vertical transactions in, 450
- Micro Leader Business v. Commission*, 98–100

- Microsoft (NAP) case*, 153–4  
*Microsoft (Tying) case*, 149–50  
*Microsoft Corp v. Motorola*, 61, 70–2, 226–7  
 Microsoft lawsuits, 10–12  
   damage to company from, 49  
   design protection in technology and, 380–4  
   essential facilities doctrine in, 390–1  
   EU litigation of, 386, 404–7  
   exceptionalism in, 98–100  
   limits of antitrust principles in, 384–7  
   SAIC Regulation (China) concerning, 484–5  
   standards-based approach in, 110–11  
   tied products/tying arrangements in, 404–7  
*Microsoft/Nokia merger*, 170–1, 177–8, 470–4  
*Miller International*, 342–4  
 Ministry of Commerce (China) (Mofcom)  
   cases reviewed by, 469–70  
   establishment of, 468–70  
   General Electric-Shenhua Group joint venture and, 474–6  
   market power assessment in merger control by, 472–3  
   remedies for mergers and, 473–4  
   SEPs-related mergers and, 470–4  
 misleading promotions, online resale price maintenance facilitation of, 433–4  
 misuse doctrine  
   bundling and innovation and, 392–4  
   tying arrangements and, 408  
 mixed bundling, discounts and rebates and, 394–8  
 modularity, information technology competitive dynamics, 453–5  
 monitoring costs, online resale price maintenance and lowering of, 431–3  
 monopoly power  
   Chinese Patent Law and, 129–30  
   competition and, 215–20  
   compulsory licensing and, 216–18  
   cooperative commercialization and, 13–14  
   copyright protection and, 210  
   cross-licensing agreements and, 219  
   design protection and, 380–4  
   disclosure and deception violations and, 236–8  
   duration of IP protection and, 211  
   economics of antitrust and, 82–3  
   exploitative abuses of IP and, 222–4  
   intellectual property and, 204–20  
   Japanese restrictions on, 139–40  
   Lerner index of, 213–14  
   market power and, 215  
   markups and demand elasticity, 215–16  
   Microsoft lawsuits and, 10–12, 380–4  
   network effects and, 45–6  
   patent pooling and, 218–19  
   patent protection and, 206–7  
   in pharmaceuticals industry, 26–39  
   properties of, 215  
   rule of reason and, 28  
   Schumpeterian competition and, 49–51  
   screen, application of, 28–32, 38–9  
   standard setting organizations and, 219–20  
   trademark registration and, 210–11  
   trade secrets law and, 207–8  
   tying arrangements and, 406–7  
   welfare consequences of, 82–3  
 Monopoly Regulation and Fair Trade Act (MRFTA) (Korea)  
   determination of illegality in, 163  
   excessive pricing investigations and, 234–5  
   interagency cooperation and, 159–60  
   IPR abuse cases and, 173  
   IP regulation under, 160–1  
   Korean Free Trade Commission IPR guidelines and, 162–3  
   post-expiration royalties cases and, 240–1  
*Morton Salt Co. v. G.S. Suppiger Co.*, 409  
*Moser, Petra*, 218–19  
*Motion Picture Patents v. Universal Film Mfg. Co.*, 407–8  
 Motorola  
   European litigation involving, 231–3  
   FTC investigation of, 227, 233–4  
   patent holdup disputes and, 251–5  
 MPEG-LA pool licenses, 363  
 MPHJ Technology Investments, 260  
 multi-homing agents  
   Big Data and, 299  
   two-sided markets and, 44–5  
*Murphy case*, 339–44  
   EU competition law and, 354  
   exhaustion doctrine in interpretation of, 347–8  
   facts and ruling in, 345–6  
   scope of, 351–2  
 Nalebuff, Barry, 397  
 Nash bargaining  
   joint negotiations with standard setting organizations, 67  
   license fees and costs of innovation, 14–15  
 National Development and Reform Commission (NCR) (China)  
   establishment of, 120–1, 468–70  
   holdup of patent violations and, 256–7  
   investigation of Qualcomm by, 131, 133–5, 480–1  
   IP–antitrust regulatory practices of, 121–9, 229–31  
   IPR-related abuses in mergers and, 478–86  
   post-expiration royalties cases and, 240

- National Disease and Therapies Index (NDTI)  
 dataset, 31
- Nature of the Firm* (Coase), 364–5
- Negotiated Data Solutions (N-Data)*  
 FTC investigation of, 227–9, 233–4  
 patent ambush in, 249–50
- net neutrality  
 FCC and, 53–4  
 Internet economics and, 46–7
- net present value, innovation economics and,  
 205–6
- Netscape, Microsoft lawsuit and, 10–12, 380–4,  
 386–7
- network effects  
 antitrust and role of, 45–6  
 antitrust impact on information technology and,  
 384–7  
 of Big Data, 305–8  
 information technology competitive dynamics  
 and, 453–5  
 Internet two-sided markets and, 43–7  
 mergers and, 389–90  
 net neutrality and, 46–7  
 Schumpeterian competition and, 50–1
- network goods, innovation and antitrust policies  
 and, 4–5
- New Chemical Entity (NCE), FDA process for,  
 22–3 n.4
- New Drug Application (NDA), 22–3  
 reverse payment cases and, 26–7
- new entrants, resale price management and safe  
 harbor for, 437–8
- new products defense, tied products/tying  
 arrangements and, 420
- New York v. Actavis* case. *See also* *FTC v. Actavis*  
 anticompetitive conduct in, 26–7  
 product hopping in, 87–9  
 reverse payment principle in, 89–90
- Nicsand, Inc. v. 3M Co.*, 399–400
- Nielson/Arbitron* case  
 antitrust policy and, 308–10  
 horizontal merger effects in, 460–1
- Nine West* case, 436–7
- no-authorized-generic (no-AG) promises, drug  
 patent settlements and, 322–4
- Nobelpharma* case, 275–7
- no-contest/no-challenge clauses, NDRC  
 Qualcomm case in China and, 135, 480–1
- Noerr-Pennington* doctrine, immunity from  
 antitrust and, 271–92
- Nokia/Alcatel merger, 470–4  
 Chinese review of, 256–7
- non-assertion of patent (NAP) obligations,  
 Japanese IP-antitrust rules and, 153–4, 233–4
- non-challenge clause, in Japanese patent law,  
 150–1
- non-discrimination in FRAND licensing,  
 69–70  
 damages in patent holdups and, 255–8  
 Korean focus on, 234–5
- nonexclusionary content  
 of Big Data, 299  
 grant-back obligations and, 150  
 patent pooling and, 369–72  
 standard setting organizations and, 219–20
- nonobviousness requirements  
 in patent protection, 206–7  
 product hopping and, 88–9
- nonpracticing entities (NPEs)  
 FRAND licensing and, 73  
 Korean IPA regulations and, 158–9, 178  
 Korean patent protections for, 170
- nonprice competition, privacy as, 303–4
- non-replicable assets, information technology  
 competitive dynamics and, 453–5
- nonrivalrous content and products  
 Big Data and, 299  
 patent pooling and, 368–9
- Notice on Institutional Establishment (China),  
 468–70
- Novel Corporation, complaints against Microsoft  
 by, 380–4, 386–7
- novelty requirement in patent protection, 206–7
- Nungesser and Eisele* case, 112–15, 342–4
- Obama, Barack, 257–8
- OEMs  
 design production in computers and, 382–3  
 disclosure and deception violations by, 236–8
- off-label drug use  
 manufacturers' research sponsorship for  
 exploring, 32 n.19  
 monopoly power screen and, 30–1
- Ohlhausen, Maureen, 294–5
- Oihoo v. Tencent*, 131
- Okuliar, Alexander P., 294–5
- online markets. *See also* Internet  
 Big Data role in, 294–7  
 country of origin principle for transmissions,  
 349–50  
 EU copyright rules and, 348–9  
 EU digital single market strategy and, 339–41  
 European competition law and transmission of  
 content in, 352–3  
 harm to competition from Big Data and, 300–8  
 horizontal mergers and, 458–62  
 limits of Big Data on, 299–300  
 mobile online advertising and, 461

- online markets. (cont.)  
*Murphy* case on cable and satellite copyright and, 344–8  
 platform differentiation in, 300  
 resale price maintenance on, 425–40  
 open access remedies, information technology and, 451  
 open-ended content of exceptionalism, 104–5  
 open source licensing arrangements, 358–9  
 Ordovery, J., 10  
 originality condition, copyright protection and, 210  
*Ortho Diagnostic Systems, Inc. v. Abbott Laboratories, Inc.*, 394–8  
 Ostrom, Elinor, 364–5  
*Ottung* case, 115  
 output  
 complementarity of products and, 388–90  
 express collusion and limitations on, 368–9  
 Japanese patent protections on, 148  
 patent pooling exclusivity and, 369–72  
 resale price maintenance impact on, 434 n.35  
 Schumpeterian competition and, 49–51  
 overuse of resources, health care financing and, 24 n.5  
 Owen, Brude, 46–7  
 ownership rights  
 copyright protection and, 210  
 limits on innovation and, 48–9  
*Pachinko Patent Pool* case, 154–5  
 package licensing  
*Huawei v. InterDigital* case in China and, 131–3  
 Japanese IP–antitrust policy and, 149–52  
 Padilla, Jorge, 67, 73–5  
 pan-EU licensing, country of origin principle for  
 online transmission and, 349–50  
 parallel trading, European competition law and, 342–4  
*Paramount Bed* case, 145–6  
*Parke David* case, 95–109  
 Parker, G.C., 44–5  
 particularism, exceptionalism and, 103–4  
 Patent Act (Japan), 143–4  
 Patent Act (Korea), Monopoly Regulation and Fair Trade Act regulations and, 162–3  
 Patent Act (US), patent pooling and, 367–72  
 patent aggregators, 260–1  
 patent ambush  
 disclosure violations and, 222–4, 236–8, 245–9  
 FRAND licensing and issues of, 64–7  
 future challenges concerning, 265–6  
 in standard setting context, 249–50  
 patent-as-property theory, 89  
 patent assertion entities (PAEs), 73  
 antitrust responses to, 263–5  
 holdups by, 247, 258–65  
 judicial and legislative responses to, 261–3  
 market function of, 257–8  
 standard essential patents switch to, 257–8  
 Patent Litigation Toolkit, 261–3  
 patent protection. *See also* holdup of patents;  
 pooling of patents; standard essential patents (SEPs)  
 abuse of patent actions, Korean IP law on, 164  
 anticompetitive dispute settlement in Korea and, 169–70, 174–5  
 applications of, 85–91  
 boundary delineation and, 365–6  
 in Chinese IP–antitrust regulations, 121–30  
 disclosure and deception violations and, 236–8  
 drug patent settlements, 319–36  
 duration of, 211  
 exclusion payment, in reverse payment cases, 33 n.22  
 expired or exhausted patents, Japanese restrictions on, 148–9  
 FDA brand and generic drug approval and, 22–3  
 four-part test for infringement of, 73  
 grantback obligations, 127–9, 133–5, 150  
 inclusion in standards and, 59–62  
 inherency in EU case-law concerning, 95–109  
 injunctions for infringement of, 71–2, 145–6  
 in Japanese IP–antitrust policies, 145–6, 150–1  
 Korean IPR guidelines concerning, 163–4, 168–70, 174–5  
 limits on innovation from, 48–9  
 litigation costs of, 326–7  
 market definition and, 36, 185–6, 200–1  
 monopoly power and, 206–7  
 non-assertion of patent obligation and, 153–4  
 non-challenge clause in Japanese law and, 150–1  
 nonpracticing entities in Korea and, 170  
 patent pools, Chinese IP–antitrust regulations and, 127–9  
 in pharmaceuticals industry, 21–2  
 post-expiration royalties and, 238–41  
 restrictive licensing in Japan and, 147–51  
 reverse payment cases and, 26–7, 32–8  
 royalty stacking and, 70–1  
 scope of patent rights, 200–1  
 sham litigation doctrine and, 271–2, 281–8  
*SK Telecom* unfair licensing practices case (Korea), 175  
 standards-based approach to, 168–9  
 sufficient economic power principle and, 415–17  
 tying arrangements and, 407–13  
*Walker Process* doctrine and, 272–81  
 welfare effects of, 83–5

- patent terminators, *inter partes* review and emergence of, 262–3
- patent-term split agreements, reverse-payment drug patent settlements and, 319–20
- Patented Medicine Notice of Compliance Regulations (PM(NOC)) (Canada), 335–6
- pay-for-delay cases, anticompetitive joint conduct and, 26–7
- payments in drug patent settlements
- cash payments, 322–4
  - causation and, 331
  - European settlements, 332–5
  - large and unjustified payment threshold and, 329
  - merits of patent and, 324–5
  - pleading requirements, 329–30
  - for unrelated services, 327–8
- payment systems
- digital single market strategy (EU) and, 350–1
  - payment card market, two-sided markets and, 43–7
  - pharmaceuticals industry and role of, 21–2
- pay-per-click business model
- “click-and-query data,” 296–7
  - impact on quality and innovation of, 301–3
  - network effects and, 305–8
- pay TV services, EU investigation of, 351–2
- People’s Republic of China
- case-law involving IP–antitrust interface in, 131–5
  - de facto standards for non-SEP related mergers in, 474–6
  - future of IP–antitrust interface in, 135–6, 486–7
  - holdup of patent violations in, 256–7
  - Internet regulation in, 129–31
  - IP–antitrust interface in, 120–36
  - IPR-related abuses and merger control in, 478–86
  - market power assessment in merger control by, 472–3
  - merger control and IPR in, 467–87
  - non-SEP-related mergers in, 474–8
  - patent-involved mergers in, 476–8
  - patent law in, 129–30
  - post-expiration royalties cases in, 240
  - remedies for merger violations in, 473–4
  - SEPs-related mergers in, 470–4
- perfectly competitive market, applications of antitrust and, 85–91
- peripheral devices, design protection and product integration and, 380–4
- per-period profits, antitrust policies and innovation and, 12, 15–16
- per se rule
- bundling and innovation and, 392–4
  - coercion in tying arrangements and, 413–15
  - design protection in high tech products and, 384
  - EU coordinated conduct cases and, 112–15
  - patent holdup injunctions and, 251–5
  - portfolio effects of mergers and, 389–90
  - resale price maintenance and, 425–7, 434–9
  - tying arrangements and tied products and, 409–18
- Petit, Nicolas, 92–117
- Pfizer/Wyeth merger, 40 n.36
- pharmaceuticals industry
- antitrust and intellectual property issues in, 21–41
  - brand/generic regulations, 25–6
  - competitive effects and monopolization in, 26–39
  - coordinated vs. single firm conduct, analysis of, 26–39
  - drug patent settlements in, 319–36
  - econometric analysis of, 25 n.7, 30 n.17
  - exceptionalism in EU case-law concerning, 101–2
  - FDA brand and generic drug approval and, 22–3
  - Korean ISP law and, 174–5
  - market definition in, 189–91
  - mergers in, 39–41
  - monopoly markups and demand elasticity, 215–16
  - monopoly power screen in, 28–32
  - product development and improvement in, 21–6
  - product hopping cases in, 38–9, 87–9
  - reverse payment cases in, 32–8, 89–90, 319–20
  - sham litigation doctrine and, 286
  - third-party payors and principal/agent problem for, 23–5
- Philips* case, blocking of patents in, 361–2
- physician as decision-maker, pharmaceuticals industry and role of, 21–2, 31
- pipeline products, pharmaceutical mergers and development of, 39–41
- platform properties
- bargaining power of IT mergers and, 462–4
  - Big Data and differentiation in, 300
  - EU bundling and innovation policies and, 386
  - intermediary platforms, 43–7
  - third-party platforms, 298–9
  - two-sided platforms, 301–6
- pleading requirements, in drug patent settlements, 329–30
- pooling of patents
- blocking of patents and, 361–2
  - boundary delineation and defense, cost reduction relating to, 364–6
  - Chinese regulations concerning, 127–8

- pooling of patents (cont.)
  - collusion threats and, 367–72
  - complements vs. substitutes, 359–63
  - exclusivity and, 369–72
  - express collusion and, 368–9
  - FRAND agreements and, 372
  - innovation rates and, 372–3
  - Japanese licensing agreements and, 152–5
  - Korean IPR guidelines and, 167–8
  - limitations on complement/substitute distinction, 363
  - market divisions and, 371–2
  - monopoly power and, 218–19
  - pricing vs. conventional bundling, 366–7
  - royalty stacking and holdup, avoidance of, 360
  - rule of reason and, 358–9, 371
  - SAIC Regulation (China) concerning, 484–5
  - technology sharing and, 358–73
  - tied products and, 362–3
- portfolio effects doctrine
  - mergers and, 388–90
  - pharmaceuticals industry, 39–41
- Posner, R., 109–10, 322–4
- post-entry behavior
  - innovation and antitrust policies and, 4
  - profits of innovation, 7–9
- post-expiration royalties
  - Chinese licensing restrictions and, 127
  - prevention of exploitation and, 222–4, 238–41
- post hoc standards, rule-based approach to EU antitrust–IP intersection and, 109–17
- PowerReviews, 304–5
- predatory behavior, entrant innovation and, 10
- pre-installed software, Microsoft lawsuit and presence of, 10–12
- Presidential Council on Intellectual Property (PCIP), 160
- presumption of illegality
  - merger policy and, 445–6
  - for online resale price maintenance, 427–34, 438–9
  - in reverse payment cases, 37 n.35
- price/cost test, loyalty discounts and, 399–400
- price protection clause, in tied products/tying arrangements, 421
- pricing. *See also* resale price maintenance (RPM)
  - bargaining power of IT mergers concerning, 462–4
  - bundling and innovation and discrimination in, 393–4
  - coercion in tying arrangements through, 413–15
  - complementarity of products and, 388–90
  - discounts and rebates on bundled products, 394–8
  - excessive pricing, FRAND obligations and, 224–35
  - Japanese patent protections on, 148
  - loyalty discounts and, 398–401
  - market power and, 85–91
  - net neutrality and discrimination in, 53–4
  - non-discrimination in FRAND licensing and, 69–70
  - in patent pools, 366–72
  - patent protection and, 83–5
  - in pharmaceuticals industry, 23–5
  - resale price maintenance impact on, 434 n.35
  - Schumpeterian competition and, 49–51
  - two-sided markets and, 43–7
  - tying arrangements and discrimination in, 406–7
  - welfare consequences of monopolization and, 82–3
- Prieger, James, 55
- principal/agent problem, in pharmaceuticals industry, 23–5
- privacy, Big Data threats to, 303–4, 310–12
- private litigation
  - excessive pricing abuses and, 225–9
  - patent assertion entities and, 258–61
  - post-expiration royalties and, 238–41
- private monopolization, Japanese prohibition of, 139–40, 222–4
- private property rights, resource pooling and, 364–6
- prize of innovation
  - antitrust policy impact on, 9–10
  - determinants of, 14–15
  - size of, 7–9
- procompetitive effects
  - of Big Data, 296–300
  - data monetization and targeted advertising, 296
  - in Japanese antimonopoly laws, 139–42
  - Korean intellectual property and competition policies and, 158–9
  - Korean limitations on scope of licensing and, 165–6
  - of mergers, 388–90
  - network effects and, 45–6
  - patent pooling and, 369–72
  - pharmaceutical antitrust cases, 28
  - of resale price maintenance, 425–7, 431–3
  - reverse payments and, 32–8
  - of tied products/tying arrangements, 409–18
- product development and improvement
  - Big Data and, 296–7
  - FDA brand and generic drug approval process and, 22–3
  - in high technology industry, 380–4

- incumbent accelerated product development, 16
- innovation and, 6–10
- net present value of innovation and, 205–6
- pharmaceutical mergers and, 39–41
- in pharmaceuticals industry, 21–2
- product differentiation
  - antitrust and IP and, 183–4
  - antitrust impact on information technology and, 384–7
  - bundled products discounts and rebates and, 394–8
  - market definition and, 188–94
- product hopping cases
  - anticompetitive unilateral conduct and, 26–7
  - competitive effects of, 38–9
  - leveraging theory and, 87–9
  - monopoly power screen in, 28–32, 38–9
  - patent-as-property theory and, 89
  - rule of reason in, 28
- product incompatibility, Chinese regulation of
  - Internet services and, 130–1
- product integration
  - design protection and, 380–4
  - Microsoft lawsuits and level of, 10–12, 380–4
- product subsidization, Big Data monetization and, 296
- Professional Real Estate Investors* (PRE) case, 271–2
  - Handgards* doctrine and, 282–3
  - non-patent anticompetitive litigation and, 288–92
- profits
  - antitrust policy impact on, 15–16
  - duration of IP, 211
  - Lerner index of monopoly power and, 213–14
  - net present value of innovation and expectation of, 205–6
  - patent pooling and boundary delineation and, 364–5
  - period-by-period profits, antitrust policies and innovation and, 12
- promotional allowances, resale price maintenance
  - in online markets and, 427–8, 431–3
- Protégé International v. Commission*, 98–100, 102
- providers of Internet information services (PIIS), Chinese regulation of, 130–1
- public display, copyright protection and, 210
- public interest
  - essential facilities doctrine in Chinese IP-antitrust regulations and, 125–6
  - Japanese antimonopoly protections for, 139–40
  - patent protection and, 271–2
  - production integration and design protection cases and, 383–4
- Publicis/Omnicom* merger, 304–5
- public performance
  - copyright protection and, 210
  - exhaustion doctrine and, 341–2
- public tendering process
  - Japanese patent infringement cases and, 145–6
  - in Korean cases of IPR abuse, 171–8
- QPX airfare pricing and shopping system, 458
- Qualcomm
  - Chinese investigation of, 131, 133–5, 229–31, 256–7, 480–1
  - European investigation of, 231–3
  - Japanese litigation involving, 233–4
  - Korean ruling on SEP abuse by, 173–4, 234–5, 240–1
  - patent ambush violations by, 249–50
  - patent holdup injunctions, 251–5
- Qualcomm Inc. v. Broadcom Corp.*, 225–9, 249–50
- quality control in innovation
  - Big Data impact on, 296–7, 301–3
  - patent holdups and, 261–3
  - tied products/tying arrangements justification using, 418–20
- Rainbow Scape* case, 172
- Rambus, Inc. v. Infineon Techs, AG*, 222–4, 236–8, 249–50. *See also* *FTC v. Rambus; Hynix Semiconductor Inc. v. Rambus Inc.*
- Ramirez, Edith, 460–1
- rate determination and disclosure, FRAND
  - licensing and, 61–2, 68–9
- reasonable apprehension test, *Walker* Doctrine
  - enforcement and, 279–81
- reasonable royalty framework
  - damages in patent holdups, 255–8
  - excessive pricing and, 224–5
  - FRAND licensing and, 67
  - Korean IPR licensing conditions and, 166–7
  - market definition and, 186
  - patent disclosure and deceptive practices and, 65–6
  - patent holdup injunctions and, 251–5
  - patent infringement and, 206–7
- rebates
  - of bundled products, 394–8
  - conditional rebates, 398–401
  - to third-party payors, pharmaceuticals practice of, 23–5
- refusal to license cases
  - exceptionalism in, 98–100
  - Japanese IP licensing agreements and, 152–3
  - Korean IPR licensing guidelines and, 165
  - rules-based approach to, 110–11

- refusal to license cases (cont.)  
 SAIC Regulation (China) and, 484–5
- Regibeau, P., 116–17
- Regulation of Abusing Intellectual Property Rights to Eliminate or Restrict Competition (China), 483–6
- Regulation on the Prohibition of Conduct Eliminating or Restricting Competition by Abusing Intellectual Property Rights (China), 471–2
- regulatory policies  
 broadband innovation and, 51–2  
 EU competition law and, 352–3  
 ex post regulations, Internet economics and, 54–5  
 innovation and antitrust policies and, 3–6  
 Internet economics and, 52–6  
 merger jurisprudence in US and, 446–53  
 net neutrality and, 53–4  
 in pharmaceuticals industry, 21–2
- Reitman, David, 397
- remedies in antitrust  
 Big Data and appropriateness of, 311–12  
 Chinese remedies in merger control, 473–4  
 in EU IPR case-law, 111–12  
 in IP protection, 212  
 merger remedies, 451
- rent extraction  
 antitrust policy and, 15–16  
 cooperative commercialization and, 12–15  
 EU cases involving, 233–4  
 exploitative abuse of IP and, 222–4  
 in information technology, 386–7  
 innovation and antitrust policies and, 3–6  
 merger analysis of, 16–18  
 patent infringement and, 225–9  
*simpliciter* protections and, 238
- reproduction rights, copyright protection and, 210
- resale price maintenance (RPM)  
 burdens of proof and production in litigation concerning, 435  
 in Chinese IP–antitrust regulations, 122–4  
 future legal issues concerning, 440  
 Japanese expired or exhausted patent restriction, 148–9  
 in Japanese IP–antitrust regulations, 141–2  
 justifications for, 438–9  
 legal precedent concerning, 425–7  
 new entrants safe harbor and, 437–8  
 online markets and, 425–40  
 presumption of illegality concerning, 427–34  
 rule of reason and, 425–7, 434–9  
 safe harbor provisions concerning, 435–8
- resale services, online resale price maintenance facilitation of, 433–4
- research and development (R&D)  
 entrant investment in, 6–10  
 in high tech industries, 386 n.23  
 Japanese IP–antitrust policies and, 151  
 merger impact on, 17–18  
 pharmaceutical mergers and, 39–41  
 in pharmaceuticals industry, 21–2  
 Schumpeterian competition and, 49–51
- resource allocation, product development and improvement and, 6–10
- resource pooling, boundary delineation in, 364–6
- restrictive licenses, Japanese regulation of, 147–51
- reverse free riding, resale price maintenance and, 430–1
- reverse holdup/holdout theories, FRAND licensing and, 62–4
- reverse payment cases  
 anticompetitive joint conduct and, 26–7  
 antitrust law and, 89–90  
 in Canada, 335–6  
 cash payments, 322–4  
 causation and, 331  
 competitive effects in, 32–8  
 drug patent settlements, 320–1  
 European settlements, 332–5  
*FTC v. Actavis* ruling and, 321–2  
 illegality presumption in, 37 n.35  
 in India, 335–6  
 in Korea, 335–6  
 large and unjustified payment threshold in drug patent settlements, 329  
 merits of patent and, 324–5  
 monopoly power screen in, 28–32  
 pleading requirements in, 329–30  
 rule of reason analysis, 28  
 state law and, 331–2  
 stock market rewards for settlement of, 36–8  
 US drug patent settlements, 319–20
- Review Guidelines for Unfair Trade Practices (Korea), 162–3
- Rhone-Poulenc* case, 284
- right of communication to the public  
 EU copyright licensing and, 341–2  
 EU transmission copyright and, 353 n.64
- Ringtone* case, 154–5
- risk aversion and discounting  
 antitrust impact on information technology and, 384–7  
 drug entry dates and, 32 n.21  
 instantaneous vs. delayed entry and, 33–4  
*Ritz Camera & Image, LLC v. SanDisk Corp.*, 277–9

- Robinson-Patman Act, 386 n.23
- robust functionality doctrine, trademark registration and, 199–200
- Rockett, K., 116–17
- Royal Information Technology Corporation (RITCO)* case, 173
- royalties. *See also* post-expiration royalties
- Brulotte* rule and, 87
- Chinese IP–antitrust regulations and, 121–9, 133–5, 229–31
- damages for SEP infringement and, 73–5
- disclosure and deception violations and, 236–8
- European litigation concerning, 231–3
- excessive pricing abuses and, 225–9
- “holdups” of licensing leverage payments, 59–62
- in *Huawei v. InterDigital* case, 478–80
- Japanese IP protections and, 151–3, 233–4
- Korean IPR licensing guidelines and, 164–5
- patent pooling, avoidance of stacking and, 360
- Qualcomm* case in China and, 480–1
- royalty-free licensing, 58 n.1
- stacking of, 70–1, 224–5, 245–9, 251–5, 360
- rule-based approach
- abuse of dominance cases in EU and, 109–11
- in antitrust cases involving IPRs, 116–17
- coordinated conduct cases, 112–15
- to EU antitrust–IP intersection, 109–17
- in EU IPR remedy cases, 111–12
- IPR license pricing and terms, 112
- rule of reason
- burdens of proof and production in RPM litigation and, 435
- in drug patent settlements, 321–2, 326–9
- patent pooling challenges and, 358–9, 371
- pharmaceutical monopoly behavior and, 28
- resale price maintenance and, 425–7, 434–9
- tied products/tying arrangements and, 421–2
- Rules on Regulating the Market Order of Internet Information Services (MIIT Internet Rules) (China), 129–31
- Rysman, M., 43–7, 60
- safe harbor principle
- bundled products discounts and rebates and, 396–7
- in Chinese IP–antitrust regulations, 123–4
- established manufacturers safe harbor, RPM litigation, 436–7
- FRAND licensing and, 66–7
- in Japanese antimonopoly laws, 139–40
- Korean intellectual property and competition policies and, 158–9
- new entrants safe harbor, RPM litigation, 437–8
- resale price maintenance litigation and, 435–8
- Walker Process* doctrine and, 279–81
- sales contracts, tied products/tying arrangements and, 413–15
- Samsung Electronics* case, standard essential patents abuse and, 176
- satellite transmission
- copyright aspects of, 344–5
- EU Cable and Satellite Directive and, 344–8
- Murphy* case facts and ruling and, 345–6
- Scarlett Extended* case, 107–8
- Schering-Plough Corp. v. FTC*, 320–1
- Schmalensee, R., 3–6, 10–12, 16–18, 67, 384–7
- Schmidt, H., 97–106
- Schumpeter, Joseph, 3, 49–51
- scope of patent principle
- drug patent settlements and, 320–1
- Korean licensing regulations and, 160, 165–6
- market power and, 200–1
- rejection in drug patent cases of, 321–2
- Scott Morton, F. and Shapiro, C., 73
- Segal, I. *See* Segal and Whinston innovation model
- Segal and Whinston innovation model, 5–6
- antitrust evaluation procedures and, 18–19
- dynamics modeling and, 6–10
- static analysis of, 10–12
- self-interest seeking, holdup of patents and, 61
- SEPs. *See* standard essential patents
- sham litigation doctrine
- basic principles of, 271–2
- drug patent settlements and, 320–1
- non-patent anticompetitive litigation and, 288–92
- Shampine, Allan L., 69–70
- Shapiro, C., 44–6, 68–9, 219, 326–7
- Shapley Value method, FRAND licensing, 67 n.39
- Shelanski, H.A., 49–51, 54–5
- Shenhua Group, General Electric joint venture with, 474–6
- Sherman Act
- applications of, 85–91
- bundled pricing and, 394–8
- disclosure and deception violations and, 236–8
- essential facilities doctrine and, 390–1
- holdup of patents and, 248–9
- market definition and, 193
- Microsoft lawsuits and, 380–4
- patent pooling exclusivity and, 369–72
- sham litigation doctrine and, 281–8
- smartphone wars and, 225–9
- tying arrangements and, 408
- Walker Process* doctrine and, 271–2
- Sibley, David, 397

- Siegel v. Chicken Delight*, 412–13, 415–17  
 Simcoe, Tim, 60  
 single firm conduct  
   applications of antitrust and, 85–91  
   monopolization and, 82–3  
   in pharmaceuticals industry, 26–39  
 single-homing agents, two-sided markets and, 44–5  
*Sirena v. EDA*, 96–7  
*SK Telecom* case, 175  
 Sky UK, EC Statement of Objections to, 341, 351–3  
 slotting fees, online resale price maintenance and, 431–3  
 small but significant nontransitory increase in price (SSNIP)  
   IP–antitrust regulations and, 183  
   market definition and, 188–9  
   merger horizontal transactions and, 447–50  
 smallest salable patent practicing unit (SSPPU)  
   damages in patent holdups and, 255–8  
   damages for SEP infringement and, 73–5  
   FRAND licensing and, 61–2  
 smartphone technology  
   holdups of patents and, 245–9  
   horizontal mergers and, 461  
   litigation involving, 225–9  
   patent pooling and, 364–6  
*SmithKline Corp v. Eli Lilly & Co.*, 394–8  
 social loss  
   welfare consequences of monopolization and, 82–3  
   welfare effects of intellectual property and, 83–5  
*Société Technique Minière*, 354  
 soft law instruments, complementarity and, 106–8  
 Sokol, D. Daniel, 293–313  
*Sot Lelos kai Sia EE and Others v. GlaxoSmith Kline*, 116–17  
 South Africa, exploitative abuse of IP in laws of, 222–4  
 specific intent, in *Walker Process* doctrine, 275–7  
 specific subject matter  
   EU antitrust and intellectual property policy and, 94–8  
   inherency and, 96–106  
 Spulber, Daniel F., 56  
 SSOs. *See* standard setting organizations (SSOs)  
 standard essential patents (SEPs)  
   business models for, 73  
   China IP–antitrust regulation, 131–5, 229–31  
   Chinese mergers related to, 470–4  
   damages for infringement of, 73–5  
   disclosure and deceptive practices and, 64–7  
   dispute resolution SSOs and, 68–9  
   enforcement of antitrust laws concerning, 241–2  
   European litigation on excessive royalties for, 231–3  
   exceptionalism and particularism concerning, 103–4  
   FRAND licensing and, 60, 62–4, 173–4, 224–5, 250–8  
   holdup disputes and, 250–8  
   *Huawei v. InterDigital* case and, 478–80  
   injunctions for protection of, 71–2, 251–5  
   Japanese IP–antitrust policies and, 145–6, 233–4  
   Korean IPR guidelines and, 158–9, 168–71, 173–4, 234–5, 240–1  
   litigation issues for, 71–5  
   non-discrimination in FRAND licensing and, 69–70  
   patent pooling and, 358–9, 372  
   post-expiration royalties cases and, 240–1  
   relevant markets for, 471–2  
   royalty stacking and, 70–1  
   SAIC Regulation (China) concerning, 484–5  
   sham litigation doctrine and, 288–92  
   switch to patent assertion entities by, 257–8  
   unilateral refusal to license violations, Japanese law on, 146–7  
 Standardization Administration of China, 128  
 standards-based approach to intellectual property  
   causal connection test and, 288–92  
   coordinated conduct cases and, 115  
   exceptionalism and, 103–4  
   FRAND disputes and, 250–8  
   holdup of patents and, 245–58  
   Korean IPR guidelines and, 168–9  
   patent ambush and, 249–50  
   rule-based approach vs., 109–10  
   US litigation and enforcement involving, 227–9  
 standard setting organizations (SSOs)  
   Chinese IP–antitrust regulations and, 127–9  
   commitments in FRAND licensing to, 59–62  
   disclosure and deception violations and, 236–8  
   dispute resolution with SEPs and, 68–9  
   emphasis on fair and reasonable in, 64–7  
   FRAND licensing and, 58–9, 224–5  
   holdup of patents and, 62–4, 245–9  
   injunctions for patent infringement and, 71–2  
   joint negotiations and, 67  
   mergers of standard essential patents and, 471–2  
   monopoly power and, 219–20  
   patent ambush and, 249–50  
   patent disclosure and deceptive practices and, 64–7  
   patent pooling and, 358–9  
   sham litigation doctrine and, 288–92  
 State Administration of Industry and Commerce (SAIC) (China), 120–1

- essential facilities doctrine and, 125–6
- establishment of, 468–70
- FRAND obligations and, 127–9
- future challenges for, 135–6
- IP–antitrust regulatory practices of, 121–9, 483–6
- IPR-related abuses and, 478–86
- standard essential patent mergers and, 471–2
- State Intellectual Property Office (SIPO) (China), 128
  - Chinese Patent Law and, 129–30
- state law, US drug patent settlements and role of, 331–2
- Statement of Objections (European Commission), 351–2
- state of mind requirement, *Walker Process* doctrine and, 275–7
- static analysis of innovation, 10–12, 18–19
- Steiner, Robert L., 437–8
- stock market, reverse payments cases and impact of, 36–8
- Straus v. Victor Talking Machine Co.*, 290 n.105
- structural remedies
  - in Chinese merger litigation, 476–8
  - in merger jurisprudence, 451
- Stucke, Maurice E., 301–3
- substantial similarity principle, copyright protection and, 198–9
- substitute products
  - exclusivity in patent pooling and, 369–72
  - limits in patent pooling of, 363
  - market definition in antitrust and, 188–9
  - monopoly power constraints from, 85–91
  - patent pooling and, 359–63
- suction effect of loyalty discounts, 398–401
- sufficient economic power principle, tied products/tying arrangements and, 415–17
- sunk costs, in high tech industries, 386 n.23
- supply
  - benefit function of innovation and, 3–6
  - essential facilities doctrine and feasibility of, 125–6
  - market definition and elasticity of, 188–9
  - resale price maintenance in online markets and coercion of, 428–9
- supracompetition
  - market definition and, 188–9
  - patent holdup injunctions and, 251–5
- Supreme Court (US)
  - eBay* court decision, 73
  - exploitative abuse of IP in rulings of, 222–4
  - Handgards* doctrine and, 282–3
  - loyalty discounts on bundled products and, 398–401
  - merits of patent in drug patent settlements and, 324–5
  - patent assertion entities and, 262
  - patent pooling cases and, 361–2
  - pay-for-delay cases before, 26–7
  - per se rule and, 393–4
  - post-expiration royalties cases and, 238–41
  - quality control and good will in tying arrangements rulings of, 418–20
  - resale price maintenance rulings by, 425–7
  - rule of reason in drug patent settlements and, 326–9
  - sham litigation doctrine and, 281–8
  - tied products/tying arrangements in rulings by, 404–9
  - Walker Process* claims before, 273–4
- surcharge payments, in Japanese antimonopoly laws, 141–2
- Swanson, 65–7, 69–70
- Taft, William Howard, 222–4
- technological tie-ins, 413–15
  - sufficiency defense for, 420–1
- technology transfer agreements. *See also* information technology; telecommunications industry
  - blocking of patents and, 361–2
  - collusion and patent pooling and, 367–72
  - complementarity and, 106–8
  - exclusivity in patent pooling and, 369–72
  - holdups of patents and, 245–9
  - in Japan, 142–3
  - patent assertion entities and, 258–61
  - patent pooling and, 358–73
  - in *SK Telecomm* case, 175
- Teece, D.J., 12–13
- telecommunications industry
  - bargaining power of mergers in, 462–4
  - Chinese regulation of, 131–5, 229–31
  - Chinese SEPs mergers and, 470–4
  - ex post regulation and, 54–5
  - foreclosure of competition in, 455–8
  - FRAND licensing and, 224–5
  - holdups of patents and, 245–9
  - merger review process for, 452–3
  - net neutrality and, 53–4
- Telefonica/Vodafone/EverythingEverywhere* joint venture, 304–5
- television copyright
  - block-booking and, 411–12
  - EU laws concerning, 97–8
- territorial protection
  - country of origin principle for online transmission and, 349–50

- territorial protection (cont.)  
 EU copyright law and, 342–4, 348–9  
 in *Murphy* case, 345–6  
 pay TV operators in EU and, 351–2
- third-party developers, exclusivity in patent pooling and, 369–72
- third-party payors  
 monopoly power screen and, 31  
 in pharmaceuticals industry, 23–5
- third-party platforms  
 Big Data collection by, 298–9  
 patent pooling and, 359–63
- 3G telecommunications standard  
 Chinese IP regulations and, 131  
 FRAND licensing and, 226  
*Samsung Electric* case (Korea), 176
- 3M Company, 399–400  
 bundled discounts from, 394–8
- tied products/tying arrangements  
 anticompetitiveness of, 392–4  
 antitrust law and, 11–12, 404–7  
 case-law applications of, 409–18  
 Chinese IP–antitrust regulations restrictions on, 126–7  
 coercion or conditions relating to, 413–15  
 commerce effects of, 417  
 copyright protection and, 411–12  
 defenses to antitrust violations from, 418–21  
 EU bundling and innovation policies and, 386  
 in high tech industry, design protection and, 380–4  
 history of intellectual property and, 407–9  
*Huawei v. InterDigital* case in China and, 131–3, 478–80  
 infant industries/new products defenses for, 420  
 innovation and, 392 n.39  
 intellectual property rights and, 404–22  
 Japanese IP–antitrust policy and, 149–50  
 limits of antitrust in high technology concerning, 384–7  
 misuse doctrine and, 409  
*NDRC Qualcomm* case in China and, 133–5, 480–1  
 patent pooling and, 362–3  
 portfolio effects of mergers and, 388–90  
 price protection clause and, 421  
*Qualcomm* case in China and, 480–1  
 quality control and good will as defenses for, 418–20  
 rule of reason in, 421–2  
 SAIC Regulation (China) concerning, 484–5  
 sufficiency defense and, 420–1  
 sufficient economic power principle and, 415–17
- trademark protection and, 412–13  
 two separate products principle and, 410–13  
 unwanted products, 362–3
- Tiercé Ladbroke SA v. Commission* case, 98–100
- tiered reimbursement  
 brand/generic drug preferences and, 25–6  
 in pharmaceuticals industry, 23–5
- Time Insurance v. AstraZeneca*, 324–5, 331
- Tinder online dating site, 299–300
- Tirole, Jean, 62–4, 218–19
- TomTom/TeleAtlas merger, 304–5
- top-down negotiation, damages in patent holdups and, 255–8
- trademark protection  
 European competition law and, 342–4  
 exceptionalism in EU cases involving, 98–100  
 inherency in EU case-law concerning, 95–109  
 in Japanese IP–antitrust policies, 145  
 market definition and, 185, 199–200  
 monopoly power and, 210–11  
 sham litigation doctrine and, 272–3 n.5  
 sufficient economic power principle and, 415–17  
 two separate products principle and, 412–13
- Trade Related Aspects of Intellectual Property Rights (TRIPS), 216–18
- trade secrets law, 207–8
- Traffix Devices, Inc. v. Marketing Displays, Inc.*, 185
- transaction costs  
 merger horizontal transactions and, 447–50  
 merger policy and, 445–6  
 patent pooling and reduction of, 364–6  
 in two-sided markets, 44–5
- Treaty on the Functioning of the European Union (TFEU), 95–109  
 complementarity and, 106–7  
 coordinated conduct cases and, 112–15  
 copyright protection and, 342–4  
 drug patent settlements and, 332–5  
 exceptionalism in cases involving, 102–3, 105  
 exploitative abuse in IP law and, 222–4  
 loyalty discounts and, 400–1  
*Murphy* case and, 345–6  
 phase-out of inherency and, 97–8  
 rule-based approach to antitrust–IP intersection in, 109–17
- true network effects, in two-sided markets, 44–5
- Trusted Execution Environment (TEE), in  
 Chinese merger policies, 474–6
- Tsai, Joanna, 326–7
- Tucker, Catherine, 297–300
- 12 Monkeys* (film), 209–10
- Twentieth Century Fox Japan* (TCFJ) case, 148

- two separate products principle  
 tied products/tying arrangements and, 410–13  
 trademark protection and, 412–13
- two-sided markets  
 Internet network effects and, 43–7  
 net neutrality and, 46–7
- two-sided platforms  
 Big Data impact on, 301–6  
 network effects and, 305–8
- unfair trade practices  
 in Japanese IP law, 222–4, 233–4  
 in Korean IP law, 160–3, 165–6, 175, 177
- unilateral conduct  
 applications of antitrust and, 85–91  
 in Korean IP law, 162–3  
 monopolization and, 82–3  
 patent pooling and collusion and, 367–72  
 in pharmaceuticals industry, 26–39  
 refusal to license, Japanese IP–antitrust laws  
 and, 146–7  
 resale price maintenance in online markets and,  
 428–9
- unilateral effects theory  
 horizontal mergers and, 458–62  
 mergers and, 447–50
- United Food & Commercial Workers Local 1776 v. Teikoku Pharma USA (Lidoderm)*, 329–30
- United Shoe Machinery* case, 392–4
- United States  
 drug patent settlements in, 319–32  
 exploitation in antitrust law of, 222–4  
 FRAND excessive pricing investigations in, 225–9  
 merger jurisprudence in, 446–53  
 post-expiration royalties cases in, 238–41  
*United States v. Bazaarvoice*, 304–5, 458–62  
*United States v. General Electric*, 222–4, 368–9  
*United States v. Jerrold Electronics Corp.*, 420  
*United States v. Terminal R.R. Ass'n*, 390–1  
*Unitherm* case, 276–7, 279–81  
 Universal Mobile Telecommunications Standard (UMTS) (3G), development of, 60, 225 n.10
- Unocal* case, 236–8, 287–8
- unreasonable damage principle, essential facilities doctrine in Chinese IP–antitrust regulations and, 125–6
- unreasonable licensing, SAIC Regulation (China) concerning, 484–5
- unwanted tied product principle, patent pooling and, 362–3
- upward pricing pressure (UPP)  
 information technology competitive dynamics and, 453–5  
 unilateral effects theory and, 449
- usage. *See also* fair use  
 Big Data creation from, 298–9  
 Japanese IP agreements concerning, 152  
 US Antitrust Guidelines for the Licensing of Intellectual Property, Korean IP law and, 163  
 usefulness requirement in patent protection, 206–7  
 user consent, Big Data and role of, 311–12  
*U.S. v. Microsoft (Microsoft III)*, 87–9  
 design protection in, 380–4  
 limits of antitrust in, 384–7  
 utility, welfare consequences of monopolization and, 82–3
- “value-added services,” Big Data enhancement of, 296–7
- vertical integration  
 market definition in IP and, 192–4  
 net neutrality and, 46–7
- vertical leveraging  
 Chinese merger control and, 473–4  
 in General Electric-Shenhua Group joint venture, 474–6  
 in mergers, 450  
 regulatory policy and, 56  
 resale price maintenance in online markets and, 428–9, 435
- Vestager, Margrethe, 352–3
- VITA standards body, 61
- VME bus technology, standards for, 61
- Wakui, Masako, 138–55
- Walker Process* doctrine  
 basic principles of, 271–2  
 current standards, 274–5  
 direct purchasers’ standing under, 277–9  
 enforcement issues with, 279–81  
 history of claims involving, 277  
 improper patent assertion and, 288–92  
 infringement litigation and, 273–4  
 knowledge and intent requirement in, 275–7
- Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp.*, 273
- Wang, Wenche, 204–20
- Wathelet (AG), 115
- wealth transfer  
 patent assertion entities and, 258–61  
 patent holdups and, 247–8  
 welfare consequences of monopolization and, 82–3
- welfare consequences of monopolization, 82–3
- WhatsApp  
 Big Data applications on, 299–300  
 FTC investigation of, 308–10

- Whinston, M. *See* Segal and Whinston innovation model
- “wholly exceptional circumstances,” exceptionalism in IPR and, 102
- Willing, R., 10
- willing licensee standard, in *Samsung Electronics* case, 176
- Windsurfing International* case, 95, 97
- “winner takes all” markets
- merger analysis and, 16–18
  - Microsoft lawsuit and, 10–12
- Wong-Ervin, Koren, 70–1
- Woods, Lebbeus, 209–10
- Wright, J.D., 49, 326–7
- Yoo, Christopher S., 46–7, 53–4, 56
- zero-pricing, in two-sided markets, 44–5
- ZF Meritor, LLC v. Eaton Corp.*, 399–400